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ABSTRACT OF DISSERTATION

DEVELOPMENT OF COCAINE HYDROLASE FOR THERAPEUTIC
TREATMENT OF COCAINE ABUSE
Cocaine abuse is a world-wide public health and social problem without a U.S.
Food and Drug Administration (FDA)-approved medication. An ideal anti-cocaine
medication would accelerate cocaine metabolism producing biologically inactive
metabolites by administration of an efficient cocaine-specific exogenous enzyme.
Recent studies in our lab have led to discovery of the desirable, highly efficient human
cocaine hydrolases (hCocHs) that can efficiently detoxify and inactivate cocaine
without affecting normal functions of central nervous system (CNS). Preclinical and
clinical data have demonstrated that these hCocHs are safe for use in humans and
effective for accelerating cocaine metabolism. However, the actual therapeutic use of a
hCocH in cocaine addiction treatment is limited by the short biological half-life (e.g. 8
hours or shorter in rats) of the hCocH.
In the investigation described in this thesis, we have demonstrated that mCocH
and hCocH have improved the catalytic efficiency of mBChE and hBChE against
cocaine by ~8- and ~2000-fold, respectively, although the catalytic efficiencies of
mCocH and hCocH against other substrates, including acetylcholine (ACh) and
butyrylthiocholine (BTC), are close to those of the corresponding wild-type enzymes
mBChE and hBChE. In addition, we have identified the first
benzoylecgonine-metabolizing enzymes that can hydrolyze benzoylecgonine and
accelerate its clearance in rats. The developed LC-MS/MS method has enabled us to
simultaneously determine cocaine and nine cocaine-related metabolites in whole blood
samples.
In development of the long-acting hCocHs, we have designed and discovered a
novel hCocH form, catalytic antibody analog, which is an Fc-fused hCocH dimer
(hCocH-Fc). The hCocH-Fc has not only a high catalytic efficiency against cocaine, but
also a considerably longer biological half-life. A single dose of hCocH-Fc was able to
accelerate cocaine metabolism in rats even after 20 days and, thus, block
cocaine-induced hyperactivity for a long period of time. In consideration of the general
observation that the biological half-life of a protein drug in humans is significantly
longer than that in rodents, the hCocH-Fc could allow dosing once every 2-4 weeks, or
longer for cocaine addiction treatment in humans.
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Chapter 1: Cocaine Abuse and Anti-Cocaine Medication

Cocaine (Figure 1.1) is a powerfully addictive drug which was originally extracted
from the leaves of the Erythroxylon coca, a plant native to South America. Cocaine has
been used as a local anesthetic starting from 1884, but currently is mostly used as a
recreational drug due to its effects on the reward pathway in the brain (1). The use of
cocaine is associated with the risk of many medical problems, such as drug
dependence and acute cardiovascular effects in case of cocaine overdose. In the
United States (US), ~2.3% of population aged 16 to 64 uses cocaine, resulting in over
500,000 emergency department (ED) visits and many other problems each year

.

(2-5)

Unfortunately, there is no US Food and Drug Administration (FDA)-approved
medication specific for cocaine abuse treatment. In this chapter, the molecular
mechanisms of cocaine addiction and toxicity, and current development of potential
treatments for cocaine abuse will be discussed.

Figure 1.1 Molecular structure of (-)-cocaine free base.

1.1 Mechanism of cocaine addiction
Cocaine is one of the most reinforcing abused drugs, stimulating the reward
1

pathway of the brain and teaching the user to take it again (6-8). While cocaine produces
its acute rewarding effects by binding mainly to dopamine and serotonin reuptake
transporters and blocking them, here the focus on just dopamine transporter (DAT) as a
typical example to describe the mechanism of cocaine addiction. In the brain’s
communication system which is formed by trillions of neurons, dopamine functions as
a neurotransmitter. Normally, dopamine is released by a transmitting neuron into the
synapse, where it can bind to dopamine receptors on the receiving neuron. Then DAT
terminates dopamine synaptic transmission by recycling dopamine back into the
transmitting neuron

. If cocaine is present, it can bind to the DAT and prevent the

(9)

removal of dopamine from synapse through both blocking the initial DAT-dopamine
binding and reducing the kinetic turnover of transporter after dopamine binds with DAT.
Although the initial cocaine-binding site in the DAT does not overlap with the
dopamine-binding site, dopamine cannot reach its binding site if cocaine is bound in the
DAT as cocaine blocks the dopamine-entry tunnel. Even if dopamine binds with DAT
before the DAT-cocaine binding (cocaine can always bind with DAT in the
presence/absence of dopamine), cocaine may inhibit the conformational change of DAT
which is necessary for the transport of dopamine (10). Blocking the recycling process of
dopamine back to the transmitting neuron results in the increased level and prolonged
presence of dopamine in the synapse, which contributes to the continuous response of
the receiving neuron and therefore pleasurable effects of cocaine. Over time, in
response to this activity, the receiving neuron begins to reduce the number of dopamine
receptors on its cell surface. Meanwhile, the transmitting neuron expresses higher level
of DAT (11, 12).
Gene expression dysregulationes in the brain’s communication system (e.g.
dopaminergic pathways) are considered as the main reasons for drug seeking and
craving. For example, the up-regulation of DAT results in less dopamine available in
the synapse for neurotransmission, and the down-regulation of the dopamine receptor
weakens the dopamine signal

. Thus, for cocaine addiction treatment, it is

(13-16)

2

necessary to bring the brain’s communication system back to normal to eliminate the
drug craving. The problem is that gene expression (e.g. DAT and dopamine receptor)
can be modulated rapidly in response to stimulant effects of cocaine, but its
normalization is usually an extremely slow process, resulting in abnormal gene
expression in the brain’s dopaminergic signaling for at least one month

. In

(13, 16, 17)

addition, whenever cocaine is used during this long process of gene normalization, it
can change the brain’s communication system again for an additional month.
Considering these reasons, successfully treating cocaine addiction requires the cocaine
abuser to receive a long-term medicine to first effectively antagonize the stimulant
effects of cocaine, and then bring the function of brain’s communication system back to
normal.
1.2 Mechanism of toxic effects of cocaine
The pharmacology of cocaine toxicity is complex with effects occurring
simultaneously in several organ systems. However, the initial event of cocaine’s
toxicity for all of these systems is same: cocaine elicits its effects by binding with a
variety of proteins, including neurotransmitter transporters, receptors, voltage-gate ion
channels, and others (18). The effects triggered depend on the cocaine concentration at
the sites of action. When cocaine is taken at a low dose, it first binds with proteins with
a high affinity for cocaine. As the serum concentration of cocaine increases, target
proteins with a high affinity for cocaine begin to be saturated, meanwhile target
proteins with a low affinity for cocaine start to be occupied with cocaine and trigger
cocaine’s effect.
Cocaine elicits its toxic effects primarily by binding to noradrenergic transporters
(indirect action, modulate calcium metabolism by β-adrenergic stimulation), leading to
elevated central and peripheral norepinephrine levels, and therefore increased heart rate
(HR), blood pressure and vasoconstriction seen in cocaine users

. The

(19-23)

hypertensive and tachycardia effects of cocaine usually cause chest pain, which is the
3

most commonly reported reason for ED cases (24-26). The cardio-toxic effects of cocaine
are also mediated directly by blocking several voltage-gated ion channels including
sodium and potassium channels (direct action)
contractility and ejection fraction

, which depresses myocardial

(18, 27)

. Of these two primary cardio effects, indirect

(28)

action predominates at low dose of cocaine, whereas the direct action is more
prominent at high dose of cocaine (29, 30). In addition, cocaine stimulates the release of
endothelin-1 from endothelial cells. Endothelin-1 acts as a vasoconstrictor by inhibiting
the production of nitric oxide which is the principal vasodilator

. The use of

(30-32)

cocaine is also associated with increased thrombosis, severe oxidative stress, reactive
oxygen species production, and apoptosis in the heart muscle

. Overall, cocaine

(33-38)

affects the cardiovascular system through the pathways described above and probably
more pathways remain to be elucidated. Cocaine increases the demand of oxygen by
increasing heart rate, blood pressure, and myocardial contractility. At the same time,
cocaine decreases the myocardial oxygen supply by coronary vasoconstriction and
enhancing thrombosis. Ischemia and infarction may occur when the myocardial oxygen
demand exceed the myocardial oxygen supply

. What’s more, cocaine causes

(30)

systolic and diastolic dysfunctions, arrhythmias, atherosclerosis, and decreased
myocardial contractility and ejection fraction
related to left ventricular hypertrophy

. The long-term use of cocaine is

(39)

, prolonged deceleration time

(40)

, and

(41)

coronary endothelial dysfunction (42).
In addition to cardiovascular effects of cocaine, cocaine abuse is linked to a variety
of other medical problems including neurological effects, gastrointestinal and
respiratory complications, AIDS, cancer, and other toxicities (3, 4). Cocaine abuse also
causes drastic changes in the personality that can lead to aggressive, compulsive,
criminal and/or erratic behaviors

. Thus, cocaine abuse is costly to both individuals

(43)

and society.

4

1.3 Treatments for cocaine abuse
Disastrous medical and social consequences of cocaine make it a high priority to
develop anti-cocaine medication for treatment-seeking users

. For emergency

(44, 45)

treatment, diazepam is usually used to decrease the increased blood pressure and heart
rate, and physical cooling and paracetamol are used to treat hyperthermia; however,
there is no officially approved drug specific for therapeutic treatment of cocaine
overdose or addiction. Despite decades of effort, classical pharmacodynamic
approaches of small molecules to block or counteract the drug’s neuropharmacological
actions have not proven successful for cocaine abuse, due in part to the extreme
difficulty in antagonizing cocaine’s physiological effects without affecting normal
functions of the central nervous system (CNS)

. In principle, pharmacological

(16)

treatment for a drug of abuse can be pharmacodynamic or pharmacokinetic (46). Most
current medications for other drugs of abuse employ the classical pharmacodynamic
approach of small molecules to block or counteract the drug’s neuropharmacological
actions at one or more neuronal binding sites. The inherent difficulties of antagonizing
cocaine in the CNS led to the development of protein-based pharmacokinetic
approaches with biologics like monoclonal antibodies, vaccines that produce antibodies
in the body, and enzymes

. Compared to the small molecules used by the

(16, 47)

pharmacodynamics approach, both anti-cocaine antibodies and cocaine-metabolizing
enzymes are too large to cross the blood brain barrier, thus reducing the off-target
effects in the CNS (16, 47, 48).
1.3.1 Pharmacodynamic approach
According to the mechanisms implicated in cocaine toxicity and addiction,
decades of effort have been made to yield small molecules to antagonize cocaine’s
effect at its sites of action. While several therapeutic candidates using small-molecule
agents have been evaluated clinically (summarized in Table 1.1), none of them has
been found to be safe and effective for treating cocaine overdose or addiction. The
5

failure in the pharmacodynamic approach may due to several reasons. First, it would be
extremely difficult to antagonize cocaine’s physiological effects without affecting the
normal functions of CNS (16). As described above, the cocaine-binding site in DAT is
close to the dopamine-binding site, so a small-molecule agent that can block the
cocaine-DAT binding usually affects the dopamine-DAT binding. In this way, DAT
antagonist actually acts as a cocaine-like drug. Second, cocaine elicits its effects
through binding with a variety of target proteins in several organs and system.
Pharmacodynamic treatments that focus on only one or several proteins may not be
able to completely eliminate the effects of cocaine

(49)

. To make the matters worse,

patients may just take more cocaine in order to achieve the expected pleasurable effects
of cocaine, meanwhile increase the toxic effects of cocaine. Finally, the
pharmacological mechanisms mediating the effects of cocaine have not been fully
understood. It is difficult to find the key target protein or system for the design and
discovery of anti-cocaine small-molecule agents. Thus, treatments that do not focus on
the physiological effects of cocaine may prove more promising as medications.

6

Table 1.1 Pros and cons of various pharmacodynamics approaches for cocaine
overdose and addiction treatment
Approaches
Dopaminergic agents
-Bupropion (50)
-Buspirone(51)
-Modafinil (52-54)
-Aripiprazole (55-57)
GABAergic agents
-Vigabatrin (58)
-Topiramate (59-61)

Addiction
Addiction
Addiction Reduced cocaine use
Addiction

Negative effects
Negative effects
Limited effects
Limited effects

Addiction
Addiction Safe and well-tolerated

-Benzodiazepines (62)

Overdose

Negative effects
Negative or limited
effects.
Limited effects

Adrenergic agents
-Citicoline (63)
-Guanfacine (64)
-Doxazosin (65, 66)
-Lofexidine (67)

Purpose

Pros

Decreased
cardiovascular effects
of cocaine

Addiction Safe. Reduced cocaine
use
Addiction
Addiction Reduced cocaine use
Overdose Decrease
cardiovascular effects
of cocaine

Amphetamine analogs
-Lisdexamfetamine
Addiction Reduced cocaine use

Cons

Effects diminished over
time
Negative effects
Distinct adverse effects
Cardiovascular adverse
effects

Has abuse potential

(68)

Antipsychotic
medications (69)
Opioid antagonist
-Naltrexone (70)

Addiction

Negative effects

Addiction Reduced cocaine
craving

Limited effects

1.3.2 Pharmacokinetic approach
The pharmacokinetic approach acts on cocaine itself, aiming to lower the
concentration of free cocaine at sites of action, thereby modulating the physiological
effects of cocaine. Long-term reduction of (free) cocaine concentration in the brain
might prevent patients from receiving any reinforcing effects of cocaine, leading to the
7

extinction of cocaine-seeking and cocaine-taking behaviors. In addition, acutely
reducing the peripheral concentration of free cocaine could minimize the toxic effects
of cocaine (e.g. the cardiovascular effects)

. To reduce the concentration of free

(71)

cocaine in both blood and brain, either anti-cocaine antibody or cocaine-metabolizing
enzyme can be used to sequester cocaine in the blood or hydrolyze it, respectively,
before cocaine reaches its site of action. Binding or hydrolyzing all cocaine molecules
is not necessarily required, because for humans, “at least 47% of the transporters had to
be blocked for subjects to perceive cocaine’s effects” (72); however, the capability of the
pharmacokinetic approach to keep the cocaine below its minimally effective
concentration should not be easily overcome by taking more cocaine. Thus, to the
success of long-term treatment of cocaine addiction, there are three key factors: (1)
Sufficient pharmacokinetic capability to keep the cocaine concentration in the brain
lower than the threshold required to produce detectable physiological effects; (2)
Making it impractical for cocaine abusers to overcome the treatment effect by
increasing drug intake; (3) Long-term effect to avoid frequent administrations for the
treatment.
1.3.2.1 Immunological strategy
The immunological strategy aims to bind cocaine with an anti-cocaine antibody in
the periphery, which blocks its access to the CNS to exert physiological effects,
meanwhile making cocaine not available to activate receptors or ion channels in
peripheral organs to generate the toxic effects

. To completely eliminate cocaine’s

(71)

effects, it is necessary for the immunological strategy to generate sufficient
anti-cocaine antibodies in the body, with not only a high binding affinity but also a
great specificity for cocaine. The anti-cocaine antibody should not bind with any other
compounds, such as neurotransmitters and endogenous cocaine-metabolizing enzymes,
to avoid any interference with normal physiological functions (71).
The immunological strategy can be administered by either passive monoclonal
8

antibody or active vaccine

. Each approach has its own advantages and

(73-75)

disadvantages. For the vaccine-approach, it requires weeks to months to generate
active immunity. However, once the immunity is generated, a certain level of
anti-cocaine antibody can persist for a long period of time. An anti-cocaine vaccine,
therefore, might be useful for the long-term treatment of cocaine addiction, but not for
treating acute cocaine overdose. In contrast, injected anti-cocaine antibody can
immediately block cocaine’s access to sites of action, thus eliminating the
physiological effects and acute toxic effects of cocaine

. One main potential

(76, 77)

disadvantage of the antibody-approach is the need of large doses of the therapeutic
agent (71).
The drug-protein conjugate vaccines for cocaine abuse treatment have been
explored in clinical trials. For example, in a double-blind, placebo-controlled clinical
trial of a cocaine vaccine which was made by covalently linking succinylnorcocaine to
cholera B (SNC-rCTB), subjects received five vaccinations of vaccine or placebo. The
treatment was safe and there were no serious side effects observed (78). Compared to the
subjects received vaccinations of placebo and subjects with low levels (< 43 μg/ml) of
serum anti-cocaine antibody, those attained high levels of anti-cocaine antibody (> 43
μg/ml) had significantly more cocaine-free urines (one of main outcome measures).
The proportion of subjects having considerably reduced cocaine use was significantly
greater in the subjects with high IgG anti-cocaine antibody levels than that in subjects
with low IgG anti-cocaine antibody levels. However, only 38% of patients developed
relatively high levels of anti-cocaine antibody following multiple vaccinations (78). The
results of a Phase III clinical trial of this vaccine also demonstrated that those more
vaccinated than placebo subjects attained abstinence for at least two weeks, and the
high IgG group had the most cocaine-free urines for the last two weeks of treatment,
but neither were significant

. Current effort is focused on new vaccines (e.g.

(79)

produced by linking hapten to a new carrier-agent
concentration of anti-cocaine antibodies

) that can provide a higher

(80)

. Recent work has yield effective

(77)
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monoclonal antibodies with a very high affinity for cocaine. Preclinical studies have
demonstrated that an anti-cocaine antibody can modify the drug-seeking and taking
behaviors in animal models; however, a large amount of antibody is required (77, 81, 82).
However, there is no anti-cocaine monoclonal antibody has been studied in human.
While immunotherapy provides some promise for treating cocaine abuse and can
significantly reduce the drug seeking and drug-intake, its chief problem is obvious: one
binding site of antibody binds stoichiometrically with cocaine

. There is no

(16, 48)

guarantee that a vaccine or antibody approach can completely eliminate drug reward,
as the effects of any given level of anti-cocaine antibodies can be overcome with either
repeated cocaine dosing or increasing the dose. The immunological strategy might
work when the plasma concentration of cocaine is low (16). However, once the antibody
is saturated by cocaine, unbound cocaine molecules are still free to either cross the
blood-brain barrier to elicit their physiological effects, or activate other targeting
proteins to produce toxic effects (16).
1.3.2.2 Cocaine-metabolizing enzyme
Unlike

the

stoichiometric

binding

of

an

antibody

with

drug,

a

cocaine-metabolizing enzyme can not only bind with cocaine, but also degrade cocaine
to free itself for further binding and reaction. Each enzyme molecule can degrade
multiple drug molecules, depending on the turnover number (catalytic rate constant kcat)
and

Michaelis-Menten

constant

(KM).

Administration

of

an

efficient

cocaine-metabolizing enzyme can dramatically accelerate the elimination of cocaine in
both brain and blood, effects that are attributable to a rapid hydrolysis of cocaine
catalyzed by the cocaine-metabolizing enzyme

, and therefore leading to the

(83, 84)

significantly reduced toxicological and behavioral effects of cocaine

. Two

(85-87)

cocaine-metabolizing enzymes designed in Dr. Zhan’s lab, including a thermally
stable mutant of bacterial cocaine esterase (CocE)

(88)

and a highly efficient mutant of

human butyrylcholinesterase (BChE) (89), are currently under clinical development for
10

the treatment of cocaine overdose and addiction, respectively. Both enzymes have
been proven to be safe and effective as anti-cocaine agents (90-92).
1.4 Bacterial cocaine esterase
CocE cloned from the Rhodococcus strain of bacteria, which grows in the soil of
cocaine-producing plants, was recognized as the most efficient natural enzyme for
. It catalyzes the hydrolysis of cocaine at the benzoyl ester

hydrolyzing cocaine

(93, 94)

bond to produce biological inactive compounds ecgonine methyl ester (EME) and
benzoic acid. There is no other natural esterase with a catalytic activity against
(-)-cocaine (which is the naturally occurring enantiomer of cocaine) comparable to
that of CocE

. However, a major obstacle to developing CocE into a therapeutic

(95)

agent for cocaine abuse is the thermoinstability of wild-type CocE with a half-life of
only ~12 min at physiological temperature (37oC)

. Based on a rational

(88, 96)

computational approach, CocE mutants were successfully engineered with
synergistically enhanced thermal stability at 37oC

. For example, double

(88, 95, 97)

mutations (T172R/G173Q) of CocE significantly increased the half-life at
physiological temperature by more than 20-fold compared to that of the native CocE,
making the mutated CocE suitable as a potential medical agent for cocaine abuse (88).
This double mutated CocE, known as drug RBP-8000, is currently in a randomized,
double-blind, placebo-controlled trial for treatment of cocaine overdose. In the
presence of RBP-8000, the plasma concentration of cocaine was reduced by 90%
within 2 min; cocaine-induced cardiovascular effects were significantly decreased
compared to placebo

(90)

. Preclinical studies also have been carried out to evaluate the

effects of CocE mutants in reducing the use of cocaine. Injection of a CocE mutant
produced rightward shifts in the does-response curves for cocaine self-administration
and discrimination

. However, such effects cannot last long due to the short

(85)

biological half-life of the CocE mutant. The improvement of thermal stability actually
did not significantly prolong the in vivo half-life of CocE, suggesting that factors
11

beyond thermal stability of protein, such as protease degradation and glomerular
filtration, shorten the biological half-life of CocE

. Although polyethylene

(23, 97, 98)

glycol conjugation (PEGylation) further improved the in vivo lifetime of CocE, the
duration of effects of PEGylated CocE mutant (high dosage of CocE) on reducing the
reinforcing effect and toxic effects of cocaine was still short (85, 95). In addition, no other
effort has been reported to extend the biological half-life of CocE longer than that of
PEGylated CocE.
As a whole, the newly designed CocE mutant can efficiently reduce the toxic
effects of cocaine by quickly hydrolyzing cocaine into biological inactive compounds.
It is a promising drug candidate for cocaine overdose treatment, which was strongly
supported by the results of clinical studies

. The genes of CocE and thermostable

(90)

CocE mutants have been cloned and proteins can be expressed in Escherichia coli cells
in large quantities. The rapid elimination of CocE should reduce the likelihood of an
immune response in humans, and prevent the accumulation of large aggregates, which
may cause damage to capillary beds or organs (98). Thus, the thermostable CocE mutant
is a safe and effective therapeutic agent for cocaine overdose treatment, but not a
suitable medicine for long-term treatment of cocaine addiction.
1.5 Human butyrylcholinesterase
BChE, previously known as pseudocholinesterase or serum cholinesterase, can be
found in plasma and many tissues, such as liver and brain

. Purified human

(99, 100)

plasma BChE has a long history of clinical application, without any adverse events
reported

. Two clinical trials (NCT00333515 and NCT00333528) of hBChE

(100)

derived from plasma were performed by by Baxter Healthcare Corporation, showing
that human BChE is safe. BChE is the principal metabolic enzyme that catalyzes the
hydrolysis of cocaine to produce biologically inactive metabolites. Unfortunately, the
catalytic efficiency (kcat/KM) of wild-type BChE against naturally occurring (-)-cocaine
is too low (kcat = 4.1 min-1 and KM = 4.5 µM) (101) to be effective for cocaine metabolism.
12

It is highly desired to develop a mutant of human BChE with a considerably improved
catalytic efficiency against (-)-cocaine.
1.5.1 Rational protein engineering of BChE
Extensive studies have been performed to increase the catalytic activity of BChE
against (-)-cocaine by accelerating the rate-determining step of the entire catalytic
reaction process without slowing down the other steps. Through structure and
mechanism based computational design and wet experimental tests, Dr. Zhan’s group
has successfully designed and discovered a series of human BChE mutants, recognized
as true cocaine hydrolases (CocHs) in literature (86) when they have at least 1,000-fold
improved catalytic efficiency against (-)-cocaine compared to wild-type human BChE
. The most recently designed BChE mutants, such as CocH3 (the

(89, 102-104)

A199S/F227A/S287G/A328W/Y332G

mutant

of

BChE)

and

CocH4

(the

A199S/F227A/P285A/S287G/A328W/Y332G mutant of BChE), are significantly
more active against (-)-cocaine than the native CocE which is the fastest natural
enzyme that can hydrolyze cocaine (102, 104).
1.5.2 CocHs for cocaine overdose treatment
As mentioned above, an efficient cocaine-metabolizing enzyme can eliminate
cocaine’s toxicity quickly, relies on the rapid hydrolysis of cocaine catalyzed by the
enzyme. The dose of enzyme required to completely remove the toxic effects of cocaine
is negatively related to the catalytic efficiency of enzyme against cocaine. The higher
catalytic activity of enzyme, the lower dose of enzyme required for the treatment and,
thus, the lower the costs of medicine. In the cocaine lethality studies using a
thermostable CocE, at least 3.2 mg/kg (IV) of CocE was required to protect 100% of the
animals from a lethal dose of cocaine (180 mg/kg, i.p.). Pretreatment of 1.0 mg/kg (IV)
of CocE right before the injection of cocaine protected only 40% of the animals from a
lethal dose of cocaine

. In comparison with CocE, recently designed CocHs are

(105)
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more effective in protecting animals from cocaine overdose. Approximately 0.3 mg/kg
of CocH3 or 0.15 mg/kg CocH4 can produce full protection in animals from cocaine
overdose induced by a lethal dose of cocaine

. Thus, compared to the CocE,

(102, 104)

highly efficient CocHs might be more promising in treatment of cocaine overdose.
1.5.3 CocHs for cocaine addiction treatment
Using a pharmacokinetic agent, the key to successful cocaine addiction treatment
is that the treatment can continuously keep the cocaine in the body below its minimally
effective concentration. It requires the enzyme used for cocaine addiction treatment to
have not only a high catalytic efficiency against cocaine, but also a long in vivo half-life.
The human serum BChE displays high bioavailability and is long-lasting in human
circulation (106); however, the recombinant human BChE expressed in mammalian cells,
goat milk of transgenic goats, insect cells, or tobacco plants displays a short biological
half-life in the circulation of animals or human being

. The short in vivo

(103, 107-109)

half-life of the recombinant BChE in animals or humans can be explained by
incomplete

post-translational

modification,

mainly

in

glycosylation

.

(100)

Glycosylation can vary from one expression system to another system; and from lot to
lot. Although unwanted glycosylation residues can be deleted and necessary residues
can be coexpressed

, for now it is impossible to produce recombinant BChE with

(109)

exactly the same post-translational modification as that of plasma-derived BChE, no
matter what expression system used. The heterogeneity in post-translational
modification, mainly in glycosylation, makes the recombinant BChE foreign (may not
be immunogenic) to the test animals or human being, accelerating the clearance of the
enzyme and shortening its biological half-life (110).
To prolong the half-life of recombinant BChE, some efforts have been made in
some research groups. Recombinant human BChE modified chemically with
polyethyleneglycol (PEG) displayed a residence time which is 2-fold longer than that
of unmodified recombinant human BChE, suggesting that PEG-modification can
14

extend the biological half-life of recombinant human BChE

. The first one of

(111)

designed CocHs, known as CocH1 or E14-3 (the A199S/S287G/A328W/Y332G
mutant of human BChE) (89, 112), truncated after amino acid #529 was fused with human
serum albumin (HSA) to prolong the biological half-life

. This HSA-fused BChE

(86)

mutant is also known as Albu-CocH, Albu-CocH1, AlbuBChE, or TV-1380 in
literature

, TV-1380 has been proven safe and effective for use in animals

(86, 91, 92, 113)

and humans (91, 92), but its actual therapeutic value for cocaine addiction treatment is still
limited by the moderate biological half-life which is ~8 hr in rats
humans

(86)

or 43-77 hr in

; in general, the biological half-life of a therapeutic protein in humans is

(91)

significantly longer than that in rats

. A biological half-life of 43-77 hr in humans

(86)

might be good enough for a twice-weekly therapy, depending on the dose of the enzyme
used. In addition, more recently designed and discovered CocHs

(102-104)

are

significantly more active against (-)-cocaine compared to TV-1380. It is highly desired
to further engineer a more active CocH with a biological half-life longer than TV-1380.
1.6 Summary of development of treatment for cocaine abuse and specific aims of
the investigation described in this dissertation
In summary, cocaine abuse is a global problem with direct and indirect adverse
impact on human health and social welfare. Unfortunately, there is no FDA-approved
effective treatment specific for cocaine abuse. Despite decades of efforts, none of the
pharmacodynamic agents tested so far has been proven effective for treatment of
cocaine addiction or overdose. The inherent difficulties of antagonizing cocaine in the
central nervous system have led to exploring protein-based pharmacokinetic
approaches with biologics like monoclonal antibodies, vaccines that produce antibodies
in the body, and enzymes

. The pharmacokinetic approach using an efficient

(16, 47)

metabolic enzyme is recognized as a truly promising treatment strategy for cocaine
overdose and addiction (16, 86, 91, 92). Clinical studies show that the CocE mutant is safe
and efficacious for accelerating the cocaine conversion to EME and benzoic acid in
15

humans (90), but is not able to hydrolyze benzoylecgonine (a major, biologically active
metabolite of cocaine, will be discussed in more detail below) at all. TV-1380 has been
proven safe and effective for use in animals and humans (91, 92), but its actual therapeutic
value for cocaine addiction treatment is still limited by the moderate biological half-life
. The investigation described in this dissertation is mainly focused on addressing

(86, 91)

some possible concerns in the further development of promising CocHs for cocaine
abuse treatment. We have carried out kinetic characterization of an hCocH and a
mCocH for their catalytic activities against (-)-cocaine and other substrates, identified
enzymes that can hydrolyze not only cocaine, but also its major biologically active
metabolite benzoylecgonine developed a LC-MS/MS method for determining
pharmacokinetic profiles of cocaine and metabolites, and developed a long-acting form
of hCocH.
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Chapter 2: Kinetic Characterization of a Cocaine Hydrolase Engineered from
Mouse Butyrylcholinesterase

Summary: In the investigation described in this chapter, mouse BChE (mBChE)
and

an

mBChE-based

cocaine

hydrolase

(mCocH,

i.e.

the

A199S/S227A/S287G/A328W/Y332G mutant) have been characterized for their
catalytic activities against cocaine, i.e. naturally occurring (-)-cocaine, in comparison
with the corresponding human BChE (hBChE) and an hBChE-based cocaine
hydrolase (hCocH, i.e. the A199S/F227A/S287G/A328W/Y332G mutant). It has been
demonstrated that mCocH and hCocH have improved the catalytic efficiency of
mBChE and hBChE against (-)-cocaine by ~8- and ~2000-fold, respectively, although
the catalytic efficiencies of mCocH and hCocH against other substrates, including
acetylcholine (ACh) and butyrylthiocholine (BTC), are close to those of the
corresponding wild-type enzymes mBChE and hBChE. According to the kinetic data,
the catalytic efficiency of mBChE against (-)-cocaine is comparable to that of hBChE,
but the catalytic efficiency of mCocH against (-)-cocaine is remarkably lower than
that of hCocH by ~250-fold. The remarkable difference in the catalytic activity
between mCocH and hCocH is consistent with the difference between the
enzyme-(-)-cocaine binding modes obtained from molecular modeling. Further, both
mBChE and hBChE demonstrated substrate activation for all of the examined
substrates ((-)-cocaine, ACh, and BTC) at high concentrations, whereas both mCocH
and hCocH showed substrate inhibition for all three substrates at high concentrations.
The amino-acid mutations have remarkably converted substrate activation of the
enzymes into substrate inhibition, implying that the rate-determining step of the
reaction in mCocH and hCocH might be different from that in mBChE and hBChE.
The main results described in this chapter have been published (114).
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2.1 Why a cocaine hydrolase engineered from mouse butyrylcholinesterase is
interesting
Previous efforts of Dr. Zhan’s group were focused on improving the catalytic
activity of hBChE against (-)-cocaine, leading to discovery of various hBChE mutants
(89, 101-104, 115-117)

with a considerably improved catalytic efficiency towards that drug.

The highly efficient hBChE mutants, such as A199S/S287G/A328W/Y332G (kcat =
3060 min-1 and KM = 3.1 M) (89, 112) or A199S/F227A/S287G/A328W/Y332G (kcat =
5700 min-1 and KM = 3.1 M)

, can be described as CocH. Initial experiments in

(102)

rats and mice showed that CocH is likely to be effective as an enzyme therapy or gene
therapy for treating cocaine abuse by greatly reducing the reward value of a given
drug dosage

. In addition, we have not seen any acute toxicity of

(83, 86, 102, 103, 118-125)

hCocH in mice or rats nor have other investigators found that wild-type hBChE
elicited adverse effects in experimental animals

. Two clinical trials

(126-128)

(NCT00333515 and NCT00333528) of hBChE have been performed by Baxter
Healthcare Corporation, although the clinical data have not been made available.
Not surprisingly, some mice and rats eventually develop antibodies against
hBChE and hCocH, accelerating the clearance of these enzymes and lowering their
plasma levels

, although no immune response is noted when mouse BChE

(122)

(mBChE) is injected into mice

. This outcome was expected because hBChE

(129)

shares only ~80% sequence identity with its rodent counterparts

. We deemed it

(130)

unlikely that human beings would generate antibodies to hCocH as the mutated
residues are not exposed on the surface but occupy a deep and narrow catalytic gorge.
Nonetheless, the mouse response called for further experiments to test the hypothesis
that mutations in the catalytic site are not antigenic. Therefore we developed a
conspecific

cocaine

hydrolase

with

equivalent

mutations

in

mBChE:

A199S/S227A/S287G/A328W/Y332G, designated mouse CocH or “mCocH”. The
catalytic properties of mCocH were compared with those of mBChE, hBChE, and
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hCocH, and it was incorporated into viral gene transfer vector for in vivo studies with
the aim of avoiding complications from an immune response in the animals.
In fact, initial gene transfer experiments with mCocH showed that very high
levels of enzyme protein could be generated, on the order of 1000-fold above the
native mBChE background level

. However, the levels of cocaine hydrolysis did

(122)

not increase to the extent achieved with hCocH. This outcome suggested that although
mCocH and hCocH contain similar mutations, their catalytic efficiencies with
(-)-cocaine are different, and results from the gene transfer study were consistent with
this interpretation

. To explore the reason, in the study described in this chapter,

(122)

mBChE and mCocH proteins were compared with hBChE and hCocH in regard to
catalytic properties against (-)-cocaine and various other substrates. In addition,
homology modeling and molecular dynamics (MD) simulations (carried out by Dr.
Xiaoqin Huang) were used to compare structural features of the two mutated enzymes.
As will be shown in this chapter, the catalytic efficiency of mCocH against
(-)-cocaine is indeed lower than that of hCocH, and computational modeling of the
detailed three-dimensional (3D) structures provides some insight into the reasons for
this conclusion, which in turn may facilitate future attempts at re-engineering
enzymes for therapeutic purposes.
2.2 Materials and methods
2.2.1 Materials
The cDNA for mBChE containing N-terminal signal was kindly provided by Dr.
Palmer Taylor (Skaggs School of Pharmacy and Pharmaceutical Sciences, University
of California, San Diego, CA). Cloned pfu DNA polymerase and Dpn I endonuclease
were obtained from Stratagene (La Jolla, CA). Restriction enzyme, alkaline
phosphatase (CIP), and T4 DNA ligase were purchased from New England Biolabs
(Ipswich, MA). All oligonucleotides were synthesized by Eurofins MWG Operon
(Huntsville, AL). Vector pCMV-MCS was obtained from Agilent Technologies
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(Santa Clara, CA). The QIAprep Spin Plasmid Miniprep Kit and QIAquick Gel
Extraction Kit were obtained from QIAGEN (Valencia, CA). Chinese hamster
ovary (CHO)-S cells and FreeStyle™ CHO Expression Medium were ordered from
Invitrogen (Grand Island, NY). [3H](-)-Cocaine (50 Ci/mmol) and [3H]acetylcholine
(ACh) were purchased from PerkinElmer Life and Analytical Sciences (Waltham,
MA). Butyrylthiocholine (BTC) was obtained from Sigma-Aldrich (St Louis, MO).
2.2.2 Construction of eukaryotic expression plasmids
Site-directed mutagenesis for obtaining the mCocH cDNA was carried out using
the QuikChange method

. The cDNA for full-length mBChE or mCocH was

(131)

constructed in a pCMV-MCS expression plasmid by using restriction enzyme EcoR I
to digest the original vector and cDNA. Before the ligation, alkaline phosphatase (CIP)
was used to dephosphorylate the 5' end of vector. Gel-purified cDNA was ligated with
pCMV-MCS vector using T4 DNA ligase. Plasmids encoding hBChE and hCocH
were obtained as previously described (102).
2.2.3 Protein expression and purification
All proteins (m/hBChE and m/hCocH) were expressed in CHO-S cells separately.
Cells were incubated at 37°C in a humidified atmosphere containing 8% CO2, and
transfected with plasmids encoding various proteins using TransIT-PRO®
transfection kit once cells had grown to a density of ~1.0 × 106 cells/ml. The culture
medium (Gibco® FreeStyle™ CHO expression medium with 8 mM glutamine) was
harvested 7 days after transfection. Secreted enzyme in the culture medium was
purified by a two-step approach described previously

, including ion exchange

(83)

chromatography using QFF anion exchanger and affinity chromatography using
procainamide-sepharose. Pre-equilibrated procainamide-sepharose was added into
protein sample purified by ion exchange chromatography, and incubated for 3 h with
occasional stirring. After washing the column with 20 mM potassium phosphate, 1
20

mM EDTA, pH 7.0 until OD280 < 0.02, enzyme was eluted by buffer containing 0.3
M NaCl and 0.1 M procainamide-HCl. The eluate was dialyzed in phosphate buffer,
pH 7.4 by Millipore centrifugal filter device. The entire purification process was
carried out in a cold-room at 4°C. Concentration of the active enzyme was determined
through active site titration with diisopropylfluorophosphate (DFP) as described
previously (122). Purified enzymes were stored at 4°C before enzyme activity assays.
2.2.4 Enzyme activity assays
The catalytic activities of enzymes against (-)-cocaine were determined with a
radiometric assay based on toluene extraction of [3H](-)-cocaine labeled on its
benzene ring. 150 μl enzyme solution (100 mM phosphate buffer, pH 7.4) was added
to 50 μl [3H](-)-cocaine solution with varying concentration. The reactions were
stopped by adding 200 μl of 0.1 M HCl which neutralized the liberated benzoic acid
while ensuring a positive charge on the residual (-)-cocaine. [3H]Benzoic acid was
extracted by 1 ml of toluene and measured by scintillation counting. The assays to
determine catalytic activity with [3H]ACh differed only in that the reaction was
stopped with 200 µl of 0.2 M HCl containing 2 M NaCl. To determine catalytic
activities of enzymes against BTC, UV-Vis spectrophotometric assays were carried
out in a GENios Pro Microplate Reader (TECAN, Research Triangle Park, NC) with
XFluor software. 100 µl enzyme solution was mixed with 50 µl of 25 mM
dithiobisnitrobenzoic acid and 50 µl of BTC in varying concentrations. Reaction rates
were measured by recording the time-dependent absorption at 450 nm. All
measurements were performed at 25oC. Kinetic data were analyzed by performing
non-linear, least-squares fitting to Eq.(2.1) (which accounts for the potential
secondary binding site of the enzyme, i.e. a peripheral anionic binding site around
D70) (132, 133).

V

Vmax (1  bS / KSS )
(1  KM / S )(1  S / KSS )
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(2.1)

In Eq.(2.1), S represents the concentration of the substrate, Vmax = kcat[E] in which [E]
is the enzyme concentration, Kss is a binding constant for substrate at the secondary
binding site, and b is a factor reflecting whether or not there is a substrate
activation/inhibition. When b = 1, there is no substrate activation or inhibition, and the
enzymatic reaction follows Michaelis-Menten kinetics. There is substrate activation
when b > 1, and substrate inhibition when b < 1. Kinetic data were analyzed with
Microsoft Excel, coding Eq.(2.1) for non-linear fitting .
2.2.5 Homology modeling
The 3D structure of mCocH was modeled based on our previously refined 3D
structure

(102, 134)

of hCocH as a template. The hCocH structure was refined through

MD simulations and hybrid quantum mechanics/molecualr mechanics (QM/MM)
calculations
(135)

(102, 134)

starting from the X-ray crystal structure (PDB entry code: 1P0P)

available for hBChE. With the refined hCocH structure as a template, a 3D

structure of mCocH was constructed and refined using the Protein Modeling module
of Discovery Studio (Version 2.5.5, Accelrys, San diego, CA). The amino-acid
sequence of mBChE was directly extracted from the PubMed website (NCBI access
No. AAH99977), with the sequence changes necessary to generate the sequence of
mCocH. The sequence alignment was generated by using ClusterW with the Blosum
scoring function

. The best alignment was selected according to both the

(136, 137)

alignment score and the reciprocal positions of the conserved residues between human
and mouse proteins, particularly the residues forming the catalytic triad
(S198-H438-E325) and the oxyonion hole (G116-G117-A/S199). The sequence
identity between mCocH and hCocH reached 80%. The coordinates of the conserved
regions were directly transformed from the template structure, whereas the
non-equivalent residues were mutated from the template to the corresponding ones of
mCocH. The side chains of those non-conserved residues were relaxed during the
process of homology modeling in order to remove the possible steric overlap or
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hindrance with the neighboring conserved residues. The initial structure of mCocH
was subject to energy minization by using the Sander module of the Amber program
(138)

with a conjugate gradient energy-minimization method and a non-bonded cutoff

of 10 Å. First, the structure of mCocH was solvated in an orthorhombic box of TIP3P
water molecules

(139)

with a minimum solute-wall distance of 10 Å. Standard

protonation states at physiological environment (pH ~7.4) were used for all ionizable
residues of the proteins, and the proton positions were set properly on the N1 atom
of histidine residues. Additional Cl- ions were added to the solvent as counter ions to
neutralize the system. The final system size was about 94 Å  91 Å × 87 Å, composed
of 62,489 atoms, including 18,555 water molecules. The first 2,000 steps of the
energy minimization were carried out for the backbone while the side chains were
fixed, and then the next 60,000 steps for the side chains and water molecules. Finally,
the system (mCocH) was energy-minimized for 6,000 steps for all atoms, and a
convergence criterion of 0.001 kcal mol-1 Å-1 was achieved.
2.2.6 Molecular dynamics (MD) simulation
Using the homology model of mCocH, we further examined how mCocH binds
with (-)-cocaine. First, (-)-cocaine was docked into the binding site, giving a binding
mode similar to that for the corresponding hCocH binding with (-)-cocaine through
the superposition. The atomic charges for (-)-cocaine were the restrained electrostatic
potential (RESP) charges determined and used in our previous studies on hBChE and
hCocH interacting with (-)-cocaine

. MD simulations were carried out on the

(89, 102)

mCocH-(-)-cocaine binding complex by using the Sander module of the Amber
program. Each system was slowly heated to 300 K by the weak-coupling method (140)
and then equilibrated for 50 ps. During the MD simulations, a 10 Å non-bonded
interaction cutoff was used and the non-bonded list was updated every 1,000 steps.
The particle-mesh Ewald (PME) method

(141)

was applied to treat long-range

electrostatic interactions. The lengths of covalent bonds involving hydrogen atoms
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were fixed with the SHAKE algorithm

, enabling the use of a 2-fs time step to

(142)

numerically integrate the equations of motion. Finally, the production MD was kept
running for 4.0 ns with a periodic boundary condition in the NTP (constant
temperature and pressure) ensemble at T = 300 K with Berendsen temperature
coupling and at P = 1 atm with anisotropic molecule-based scaling (143).
2.3 Catalytic parameters kcat and KM
The kinetic data are depicted in Figures 2.1 to 2.3, and the obtained kinetic
parameters are summarized in Table 2.1. As seen in Table 2.1, compared to hBChE,
mBChE has a smaller kcat value (1.4 min-1 vs 4.1 min-1) and a smaller KM value (1.6 µM
vs 4.5 µM) against (-)-cocaine. Overall, the catalytic efficiency of mBChE against
(-)-cocaine (kcat/KM = 8.8 × 105 min-1 M-1) is comparable to that of hBChE (kcat/KM = 9.1
× 105 min-1 M-1). Concerning the effects of the mutations, hCocH has a ~2000-fold
improved catalytic efficiency against (-)-cocaine compared to hBChE. From that
standpoint, one might expect that mCocH would also have considerably greater
catalytic efficiency against (-)-cocaine than mBChE. In fact, as seen in Table 2.1, the
kcat of mCocH against (-)-cocaine is ~180-fold larger than that of mBChE against
(-)-cocaine, but the KM of mCocH against (-)-cocaine is also larger than that of mBChE
against (-)-cocaine (~22-fold). So, the improvement in kcat is compromised by the
significant increase of KM, resulting in only ~8-fold improved catalytic efficiency over
mBChE (kcat/KM = 7.1 × 106 min-1 M-1). As a result, compared to hCocH, mCocH has
~250-fold lower catalytic efficiency against (-)-cocaine.
According to the kinetic parameters in Table 2.1, against substrate ACh, mBChE
has a slightly smaller kcat value (38400 min-1 vs 61200 min-1) and a slightly larger KM
value (400 µM vs 148 µM) compared to hBChE. Therefore, the catalytic efficiency of
mBChE against ACh is ~4-fold lower than that of hBChE. Concerning the mutational
effects on hydrolysis of ACh, both mCocH and hCocH exhibit catalytic efficiencies
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only slightly lower than those of the wild-type enzymes (mBChE and hBChE). In
other words, the mutations caused no substantial effect.
Against substrate BTC, mBChE has a slightly larger kcat value than hBChE (35600
min-1 vs 29500 min-1) but a significantly larger KM value (72 µM vs 17 µM). Overall,
the catalytic efficiency of mBChE against BTC is ~3-fold lower than that of hBChE.
Concerning the mutational effects on enzyme activity against BTC, the catalytic
efficiency of mCocH is only slightly lower than that of mBChE, whereas the catalytic
efficiency of hCocH is only slightly higher than that of hBChE. Overall changes in the
catalytic efficiency against BTC are probably not physiologically significant in either
mutated enzyme.
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Table 2.1 Kinetic parameters determined for (-)-cocaine, ACh, and BTC hydrolyses
catalyzed by mBChE, mCocH, hBChE, and hCocH. This table came from ref. (114).

a

Enzyme

Substrate

mBChE
mCocH
hBChEb
hCocHc
mBChE
mCocH
hBChEd
hCocHe
mBChE
mCocH
hBChEf
hCocHe

(-)-cocaine
(-)-cocaine
(-)-cocaine
(-)-cocaine
ACh
ACh
ACh
ACh
BTC
BTC
BTC
BTC

KM
kcat
-1
(min ) (μM)
1.4
1.6
250
35
4.1
4.5
5700
3.1
38400 400
19000 210
61200 148
11900
37
35600
72
28200
99
29500
17
28000
13

kcat/KM
(min-1 M-1)
8.8 × 105
7.1 × 106
9.1 × 105
1.8 × 109
9.6× 107
9.0 × 107
4.1 × 108
3.2 × 108
4.9 × 108
2.8 × 108
1.7 × 109
2.2 × 109

RCEa
1
8.2
1
2020
1
0.94
1
0.78
1
0.58
1
1.24

Kss
(μM)
1300
1500
216
137
15200
25800
31600
30000
5000
254
3010
243

b
3.13
0.88
1.80
0.40
1.79
0.30
2.58
0.68
2.77
0.19
3.36
0.49

RCE refers to the relative catalytic efficiency (kcat/KM), i.e. the ratio of the kcat/KM

value of a mutant (mCocH or hCocH) to that of the corresponding wild-type enzyme
(mBChE or hBChE) against the same substrate.
b

The kcat and KM for hBChE against (-)-cocaine were reported in ref.(101).

The kcat and KM for hCocH against (-)-cocaine were reported in ref.(102).

c

d

The kcat and KM for hBChE against ACh were reported in ref.(86).

The kcat and KM for hCocH against ACh and BTC were reported in ref.(144).

e

The kcat and KM for hBChE against BTC were reported in ref.(118).

f
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Figure 2.1 Kinetic data obtained in vitro for (-)-cocaine hydrolysis catalyzed by
mCocH, mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1
per nM enzyme. This figure came from ref.(114).
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Figure 2.2 Kinetic data obtained in vitro for ACh hydrolysis catalyzed by mCocH,
mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1 per nM
enzyme. This figure came from ref.(114).
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Figure 2.3 Kinetic data obtained in vitro for BTC hydrolysis catalyzed by mCocH,
mBChE, hCocH, and hBChE. The reaction rate is represented in M min-1 per nM
enzyme. This figure came from ref.(114).
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2.4 Insights from molecular modeling
To understand why mCocH has much lower catalytic efficiency against
(-)-cocaine compared to hCocH, we modeled the 3D structure of mCocH binding with
(-)-cocaine for comparison with the corresponding hCocH-(-)-cocaine binding.
Depicted in Figure 2.4 are the aligned sequences of mCocH and hCocH, showing that
the overall sequence identity between these two enzymes is as high as 80%. As shown
in Figure 2.4, mCocH and hCocH share the same residues for the catalytic triad that
reacts with (-)-cocaine (S198, H438, and E325), and the same oxyanion hole residues
(G116, G117, and S199) that form hydrogen bonds with the carbonyl oxygen atom on
the benzoyl group of (-)-cocaine. Another common feature of cocaine binding with
hCocH and mCocH is that the cationic head of (-)-cocaine has a similar cation-π
interaction with the side chain of W82.
The main difference between hCocH and mCocH is that the cationic head of
(-)-cocaine interacts more favorably with the protein environment including side
chains of F73 and W328 in hCocH, compared to the corresponding interactions in
mCocH. This appears to be due to a difference in the detailed shape of the binding
pockets in the two enzymes. For example, residue #72 is an alanine in mCocH and
serine in hCocH. In hCocH, the hydroxyl group of S72 side chain forms a strong
hydrogen bond with an oxygen atom in the carboxylate moiety of the D70 side chain
(Figure 2.5C and D). This hydrogen bond apparently influences the orientation of the
aromatic ring in F73 such that the cationic head of (-)-cocaine aligns nearly parallel to
the vector normal to the plane of the aromatic ring of F73 side chain. As a result, the
MD-simulated average distance between the positively charged N atom of (-)-cocaine
and the center of the hCocH F73 side chain aromatic ring was 7.06 Å, and the
MD-simulated average distance between the positively charged N atom of (-)-cocaine
and the center of aromatic ring of W328 side chain was 5.99 Å.
In mCocH, with no hydrogen bond between the side chains of A72 and D70, the
side chain of altered residue #72 is farther away from D70 than it is in hCocH. This
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causes the orientation of the aromatic ring of the F73 side chain in mCocH to differ
substantially from that in hCocH. Due to this alteration, the hydrogen atoms on the
aromatic ring of F73 side chain in the initial model of mCocH-(-)-cocaine binding
structure seemed too close to the (-)-cocaine atoms. After further simulation, the F73
side chain pushed away from the (-)-cocaine atoms and the MD-simulated average
distance between the positively charged N atom of (-)-cocaine and the center of
aromatic ring of F73 side chain grew to 8.58 Å (1.52 Å longer than that in hCocH). The
difference in residue #72 also indirectly affected the interaction of (-)-cocaine with
W328. The MD-simulated average distance between the positively charged N atom of
(-)-cocaine and the center of the W328 side-chain aromatic ring was 6.90 Å in mCocH
(0.91 Å longer than that in hCocH). Due to the less favorable interactions of the cationic
head of (-)-cocaine with F73 and W328 side chains in mCocH, the overall binding of
(-)-cocaine with mCocH can be expected to be weaker, which is consistent with the
experimental observation that, compared to hCocH, mCocH has a significantly larger
KM value and a significantly smaller kcat value against (-)-cocaine.
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Figure 2.4 Sequence alignment between mCocH and hCocH. Stars refer to identical
residues, whereas filled period and double filled period refer to the conservative
substitutions. This figure came from ref.(114).
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Figure 2.5 The MD-simulated structures of mCocH and hCocH binding with
(-)-cocaine. (A) mCocH-(-)-cocaine binding structure; (B) and (C) plots of key
distances in the mCocH-(-)-cocaine complex versus the simulation time; (D) plot of
root-mean-squares deviation (RMSD) of the atomic positions of (-)-cocaine in the
mCocH-(-)-cocaine complex versus the simulation time; (E) hCocH-(-)-cocaine
binding structure; (F) to (H) plots of key distances in the hCocH-(-)-cocaine complex
versus the simulation time; (I) plot of the RMSD of the atomic positions of (-)-cocaine
in the hCocH-(-)-cocaine complex versus the simulation time. COC refers to
(-)-cocaine. COC(O33)---G117(H) represents the distance between the carbonyl
oxygen on the benzoyl group of (-)-cocaine and the backbone hydrogen atom of G117;
COC(O33)---S199(HG) the distance between the carbonyl oxygen on the benzoyl
group

of

(-)-cocaine

and

the hydroxyl hydrogen
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of

S199 side

chain;

COC(N+)---W328(side chain) the distance between the positively charged nitrogen of
(-)-cocaine and the center of aromatic side chain of W328; S198(HG)---H438(NE2)
the distance between the hydroxyl hydrogen of S199 side chain and the nitrogen atom
(NE2) of H438 side chain; H438(HD1)---E325(OE1/OE2) the distance between the
hydrogen

atom

(HD1)

on

the

nitrogen

atom

of

H438

side

chain;

COC(C32)---S198(OG) the distance between the carbonyl carbon on the benzoyl
group

of

(-)-cocaine

and

the

hydroxyl

oxygen

of

S198

side

chain;

D70(OD1/OD2)---S72(HG) the shortest distance between the oxygen atoms of D70
side chain and the hydroxyl hydrogen of S72 side chain; and F73(side
chain)---W328(side chain) the distance between the positively charged N atom of
(-)-cocaine and the center of aromatic ring of W328 side chain. All distances and
RMSD are given in Å. This figure came from ref.(114).
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2.5 Main insights obtained in from this investigation
Kinetic analysis reveals that the catalytic efficiencies (kcat/KM) of mBChE against
ACh, BTC, and (-)-cocaine resemble those of hBChE. After comparable substitutions
at five homologous sites in the catalytic gorge, the corresponding mutant forms
mCocH and hCocH both retain similar activities against ACh and BTC and both show
enhanced hydrolysis of (-)-cocaine. However, the magnitude of enhancement differs
radically between the two enzymes: ~8-fold with mCocH and ~2000-fold with hCocH,
leaving the mouse protein ~250-fold less efficient with (-)-cocaine than its human
counterpart. A second surprise was that ACh, BTC, and (-)-cocaine all showed
substrate activation in wild-type mouse and human BChE, but uniformly caused
substrate inhibition in both of the mutated enzymes. That result implies that the
rate-determining step of the reactions in mCocH and hCocH may differ from that in
mBChE and hBChE. These unexpected outcomes posed an interesting challenge to
rational, structure and mechanism based enzyme mutation. However, homology
modeling and molecular dynamics simulations shed light on the underlying causes. In
other words, the observed behavior was consistent with the enzyme-(-)-cocaine
binding structures obtained from molecular modeling.
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Chapter 3: Metabolic Enzymes of Cocaine Biomarker Benzoylecgonine

Summary: Enzyme therapy using an efficient cocaine-metabolizing enzyme is
recognized as the most promising approach to cocaine overdose treatment. The actual
enzyme, known as RBP-8000, under current clinical development for cocaine overdose
treatment is previously designed T172R/G173Q mutant of bacterial cocaine esterase
(CocE). The T172R/G173Q mutant is effective in hydrolyzing cocaine, but inactive
against benzoylecgonine (a major, biologically active metabolite of cocaine) at all.
Unlike cocaine itself, benzoylecgonine has an unusually stable zwitterion structure
resistant to further hydrolysis in the body and environment. In fact, benzoylecgonine
can last in the body for a very long time (a few days) and, thus, is responsible for the
long-term toxicity of cocaine and a commonly used biomarker for drug abuse diagnosis
in pre-employment drug tests

. Because CocE and its mutants are all active

(145, 146)

against cocaine and inactive against benzoylecgonine, one might simply assume that
other enzymes that are active against cocaine are also inactive against benzoylecgonine.
In the study described in this chapter, through combined computational modeling and
experimental studies, we demonstrate for the first time that human BChE is actually
active against benzoylecgonine, and that a rationally designed BChE mutant can not
only more efficiently accelerate cocaine hydrolysis, but also significantly hydrolyze
benzoylecgonine in vitro and in vivo. This sets the stage for advanced studies to design
more efficient mutant enzymes valuable for development of an ideal cocaine overdose
enzyme therapy and for benzoylecgonine detoxification in environment. The main
results discussed in the chapter have been published (147).
3.1 Cocaine overdose and benzoylecgonine
Efficient and thermally stable cocaine-metabolizing enzymes have been designed
and developed recently as potential therapeutic candidates for treatment of cocaine
overdose and addiction (88, 89, 102-104, 148). These computationally designed enzymes, that
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are mutants of human BChE or bacterial CocE, can rapidly convert cocaine to
physiologically inactive EME and benzoic acid. In particular, a thermally stable CocE
mutant (T172R/G173Q)

, known as RBP-8000

(88)

, is currently in clinical

(90)

development for cocaine overdose treatment; the human clinical trial Phase IIa has
been completed, showing that the CocE mutant is safe and efficacious for accelerating
the cocaine conversion to EME and benzoic acid in humans (90).
A potential concern for practical clinical use of the enzyme therapy for cocaine
overdose is that cocaine is also converted to benzoylecgonine (BE) by endogenous liver
carboxylesterase-1 (hCE-1) in the body (see Figure 3.1). BE is actually a more potent
vasoconstrictor than cocaine, norepinephrine, and norcocaine (145), and cerebral artery
segments are significantly more sensitive to BE than to cocaine and the other cocaine
metabolites (146). More importantly, compared to cocaine itself, BE can exist in the body
for a considerably longer period of time. For this reason, BE is a commonly used
cocaine biomarker for cocaine abuse diagnosis in human drug tests. For cocaine
overdose treatment in an ED, a patient intakes cocaine before going to the ED and, thus,
a lot of cocaine molecules have already been converted to BE in the body prior to
administration of an exogenous enzyme

. Hence, an ideal enzyme therapy for

(145)

cocaine overdose should detoxify not only cocaine itself (which is mainly responsible
for the acute toxicity and lethality), but also its long-lasting metabolite BE (which is
mainly responsible for the long-term toxicity of cocaine). However, unlike cocaine, BE
is a zwitterion extremely difficult to hydrolyze in not only human body, but also
environment

. It has been extremely challenging to efficiently hydrolyze BE for

(149)

both cocaine overdose treatment and BE detoxification in environment. In fact, CocE
and its T172R/G173Q mutant (RBP-8000) (88) are highly efficient against cocaine and
norcocaine, but inactive against BE

. To the best of our knowledge, no metabolic

(4)

enzyme of BE has ever been reported in literature. Here we report the first observation
of metabolic enzymes of BE, providing a promising starting point for future
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development of an ideal enzyme therapy for cocaine overdose and for BE
detoxification in environment.

Figure 3.1 Metabolic pathways of cocaine in humans and animals with metabolic
enzymes including BChE, hCE-1, and oxidation by cytochrome P450 (CYP) 3A4. This
figure came from ref.(147).
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3.2 Materials and methods
3.2.1 Molecular modeling
BE binding with human BChE and mutants was modeled by using our previously
modeled structures of the same enzymes
molecular dynamics (MD) simulations
complexes

(125)

. Our previous

(89, 102, 103, 116, 125, 150-152)

(103)

on the structures of enzyme-cocaine

started from the X-ray crystal structure deposited in the Protein Data

Bank (pdb code: 1P0P). For each enzyme (human BChE or mutant), BE was docked
into the active site of the enzyme by using the AutoDock 4.2 program

, as we

(153)

previously did for the enzyme binding with (-)-cocaine, norcocaine, and cocaethylene
. During the docking process, the Solis and Wets local search method (154) was used

(125)

for the conformational search and the Lamarkian genetic algorithm (LGA)

(153)

was

employed to deal with the enzyme-ligand interactions. The grid size was set to be 120 
120  120. The finally obtained enzyme-BE binding structures were the ones with the
lowest binding free energies.
3.2.2 In vitro enzyme activity assays
All enzymes (wild-type human BChE, E14-3, and E12-7) were expressed and
purified as described previously (155), and the catalytic activities of the purified enzymes
against BE (and (-)-cocaine for comparison) were determined by performing a UV-Vis
spectrophotometric assay. Using the UV-Vis spectrophotometric assay, the catalytic
activity of the enzymes against BE and (-)-cocaine were determined at the same time
under the same experimental conditions except the concentration of the enzymes and
substrates, to make sure that the known enzyme activity against (-)-cocaine can be
reproduced. The enzymatic reaction was initiated by adding 180 l of a substrate (BE
or (-)-cocaine) solution to 20 l of an enzyme solution. The final reaction systems of
BE have the initial BE concentrations of 500, 300, 200, 100, 50, 20, and 10 µM,
whereas the final reaction systems of (-)-cocaine have initial (-)-cocaine concentrations
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of 50, 30, 20, 10, 5, 2, and 1 M. The reaction temperature was 25°C, and the buffer
used was 0.1 M potassium phosphate (pH 7.4). The initial rates of the enzymatic
hydrolysis of BE/(-)-cocaine in various initial substrate concentrations were estimated
by following the change in the intrinsic absorbance peak of BE/(-)-cocaine at 230 nm
with time using a GENios Pro Microplate Reader (TECAN, Research Triangle Park,
NC) with the XFluor software. The initial reaction rates were calculated from the linear
portions of the progress curves. All assays were carried out in triplicate. The
Michaelis-Menten kinetic analysis was performed by using Prism 5 (GraphPad
Software Inc., San Diego, CA) to determine the Vmax and KM values.
3.2.3 Kinetic modeling
Kinetic modeling of (-)-cocaine in humans was performed by use of a MatLab
program (developed in house)

(125, 156, 157)

in a way similar to that of our recently

developed pharmacokinetic modeling of (-)-cocaine in the presence of a
cocaine-metabolizing enzyme

. The previously used kinetic model (155) did not

(125, 158)

involve BE. By using a one-compartment model, the present kinetic modeling also
accounted for the transformation of (-)-cocaine to BE and the subsequent BE hydrolysis
in the presence of wide-type BChE or a highly efficient cocaine-metabolizing enzyme
E12-7.
3.2.4 Subjects for in vivo studies
Male Sprague-Darley rats (200-250 g) were ordered from Harlan (Harlan,
Indianapolis, IN) and were housed initially in 2 to 4 rats per cage. All rats were allowed
ad libitum access to food and water and were maintained on a 12-hour light and dark
cycle with lights on at 8 AM in a room kept at a temperature of 21 to 22°C. Experiments
were performed in a same colony room in accordance with the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated by the National Institutes of
Health. The animal protocol was approved by the Institutional Animal Care and Use
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Committee (IACUC) at the University of Kentucky.
3.2.5 In vivo tests of BE, ecgonine, and E12-7 in rats
BE and ecgonine were provided by the National Institute on Drug Abuse (NIDA)
Drug Supply Program (Bethesda, MD). General anesthetic isoflurane was utilized with
nose cone during the administration of BE and E12-7 (or saline). Rats were injected
with saline, 0.15 or 5 mg/kg of E12-7 through tail vein 1 min before IV injection of 2
mg/kg BE (~6.9 μmole/kg). Four rats were used for each set of experiments (n=4),
About 50 to 75 μl of blood was collected from saphenous veins into capillary tubes and
immediately diluted in 100 μl of 250 μM paraoxon at 2, 5, 10, 30, 60, 90, 120, 150, and
180 min after the IV injection of BE or ecgonine. Paraoxon is an irreversible BChE
inhibitor that can stop the enzymatic hydrolysis of BE between blood sampling and
analysis. The diluted blood samples were stored at -70°C and assayed by using a high
performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method
(details described in chapter four). For determination of the active E12-7 concentration,
the collected blood samples were not diluted with paraoxon, but centrifuged to obtain
the plasma for the enzyme activity assays.
3.3 Identification of enzymes hydrolyzing BE
Our search for a metabolic enzyme of BE started from molecular docking (using a
protocol described previously (155)) which enabled us to predict whether BE may bind
with various serine esterases, including AChE, BChE and various mutants available in
our lab, in a way suitable for the enzymatic hydrolysis of cocaine benzoyl ester group.
Potential BE-hydrolyzing enzymes predicted by molecular docking were assayed in
vitro for their catalytic activity against BE (see Methods section). Because it has been
known that CocE and the T172R/G173Q mutant are active against cocaine and inactive
against BE, one might simply assume that BChE and its mutants that are active against
cocaine are also inactive against BE. Surprisingly, unlike CocE and its mutants, both
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molecular docking and in vitro activity assays consistently revealed that BChE and our
rationally designed mutant enzymes, i.e. the A199S/S287G/A328W/Y332G mutant
(E14-3)

(89)

and A199S/F227A/S287G/A328W/Y332G mutant (E12-7)(102) of human

BChE, are all active against BE. E12-7 is also known as CocH3, and E14-3 is also
known as CocH1, in literature (48, 125).
According to the enzyme-substrate binding structures obtained from molecular
docking, BChE and the two mutants all can bind with BE in a similar way as their
binding with (-)-cocaine, suitable for the desired enzymatic hydrolysis of (-)-cocaine
benzoyl ester group. Depicted in Figure 3.2A and B are the obtained structures of
wild-type BChE binding with (-)-cocaine and BE, showing that the backbone NH
groups of G117 and A199 residues (within the oxyanion hole) are all close to the
common carbonyl oxygen of the substrates such that they may form two favorable
hydrogen bonds with the carbonyl oxygen of the substrate in the anticipated transition
state

(89)

during the enzymatic reaction process for both (-)-cocaine and BE. Further,

according to the E12-7-BE binding structure depicted in Figure 3.2C, the carbonyl
oxygen of BE is also close to the hydroxyl group of S199 side chain; similar structure
(not shown) was also obtained for the E14-3-BE binding. Thus, the carbonyl oxygen of
BE may form three hydrogen bonds with G117 and S199 residues of the enzyme (E12-7
or E14-3) within the oxyanion hole in the anticipated transition state during the
enzymatic reaction process, suggesting that E12-7 (and E14-3) may have significantly
improved catalytic activity against BE compared to wild-type BChE. Based on the
modeling insights, we decided to carry out in vitro enzyme activity assays on human
BChE, E14-3, and E12-7 against BE. Depicted in Figure 3.2D to F are data obtained
from in vitro kinetic analysis on human BChE, E14-3, and E12-7 against BE.
According to the kinetic data in Figure 3.2D to F, wild-type human BChE has a kcat of
3.6 min-1 against BE comparable to its kcat against (-)-cocaine (kcat = 4.1 min-1). The
main difference is that it has a relatively larger Michalis-Menten constant value (KM =
83 M) against BE compared to its KM against (-)-cocaine (KM = 4.5 M). Notably,
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despite of the relatively lower catalytic efficiency against BE compared to its own
efficiency against (-)-cocaine, the catalytic efficiency of human BChE against BE is
actually higher than that of the known most active anti-cocaine catalytic antibody
15A10 (kcat = 2.3 min-1 and KM = 220 µM) against (-)-cocaine (159, 160).
Interestingly, compared to wild-type human BChE, both enzymes E14-3 and E12-7
that have considerably improved catalytic activities against (-)-cocaine and norcocaine
also have significantly improved catalytic activity against BE. As seen in Figure 3.2,
kcat = 23 min-1 for E14-3, kcat = 65 min-1 for E12-7, and kcat = 3.6 min-1 for the wild-type
BChE against BE. So, E14-3 and E12-7 have improved the kcat of the wild-type BChE
against BE by ~6-fold and ~18-fold, respectively. Meanwhile, E14-3 and E12-7 have
slightly larger KM values (133 M for E14-3 and 207 M for E12-7). The improvement
in kcat against BE is significant, although not as much as that (>1000-fold improvement)
against (-)-cocaine (155).

43

Figure 3.2 Data obtained from molecular docking and in vitro kinetic analysis. (A)
Wild-type BChE binding with (-)-cocaine; (B) Wild-type BChE binding with BE; (C)
E12-7 binding with BE; (D) Kinetic data for wild-type BChE against BE; (E) Kinetic
data for E14-3 against BE; (F) Kinetic data for E12-7 against BE. Indicated in the
docked binding structures are the key internuclear distances in Å. For the kinetic data,
the reaction rate (represented in nM min-1 per nM enzyme) was determined by
measuring the rate of the change of the absorbance at 230 nm. This figure came from
ref.(147).
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A: Cocaine
B: Benzoylecgonine
C: Ecgonine
D: Benzoic Acid
E: Ecgonine Methyl Ester
F: Norcocaine
G: Norecgonine Methyl Ester

dA(t)
 VmaxA(t) /(Km  A(t)) F2 A(t) /(k2  A(t)) F3 A(t) /(k3  A(t))
dt
dB(t)
 F3 A(t) /(k3  A(t))V' ' 'maxF(t) /(K' ' 'm F(t))
dt
dC(t)
V' ' 'maxF(t) /(K' ' 'm F(t))
dt
dD(t)
VmaxA(t) /(Km  A(t))V' 'maxF(t) /(K' 'm F(t))
dt
V' ' 'maxF(t) /(K' ' 'm F(t))
dE(t)
VmaxA(t) /(Km  A(t))
dt
dF(t)
 F2 A(t) /(k2  A(t))V' 'maxF(t) /(K' 'm F(t))
dt
dG(t)
V' 'maxF(t) /(K' 'm F(t))
dt
dH(t)
 F3 A(t) /(k3  A(t))
dt

H: Methanol

Figure 3.3 Reaction scheme and kinetic equations used in the kinetic modeling. This
figure came from ref.(147).

3.4 Effects of E12-7 on the pharmacokinetics of (-)-cocaine and BE
Following the identification of endogenous metabolic enzyme of BE (i.e. BChE)
and its improved mutants (E14-3 and E12-7), we wanted to know whether E12-7 may
significantly accelerate BE metabolism in the body. For this purpose, we first carried
out kinetic modeling of cocaine and its metabolites (including norcocaine and BE). The
kinetic model was based on our previous kinetic modeling (155) without accounting for
BE formation and metabolism. Using the catalytic parameters for wild-type BChE- and
E12-7-catalyzed hydrolysis of BE determined in the present study, we were able to
expand the previous kinetic model

(155)

so that we may model the possible effects of

E12-7 on the kinetic profile of BE when the plasma concentration of E12-7 is the same
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as that of endogenous BChE in human plasma ([E] = 0.07 M) (155) or higher. Briefly,
kinetic modeling of (-)-cocaine metabolism was carried out by using the kinetic
equations shown in Figure 3.3 in the presence of three enzymes: BChE or CocH (which
refers to either wild-type human BChE or E12-7) in human plasma; liver
carboxylesterase; and CYP 3A4. Concerning CocH, a typical adult has a blood volume
of ~5 L (158). Previously reported concentrations of endogenous BChE protein in human
plasma ranged from 4 to 7 mg/L (161-163), giving an average value of ~6 mg/L or ~0.07
M in terms of the total BChE protein concentration (denoted as [E]), assuming that a
tetramer of human BChE has four active sites (164, 165). According to the known kinetic
data reported previously (155) and obtained in the present study, we should have Vmax =
0.29 M min-1 and KM = 4.5 M for the wild-type BChE against (-)-cocaine, Vmax =
0.20 M min-1 and KM = 15 M for the wild-type BChE against norcocaine, and V'''max
= 0.25 M min-1 and K'''M = 83 M for the wild-type BChE against BE when [E] = 0.07
M. These kinetic parameters were used in our modeling with the wild-type BChE.
Similarly, for E12-7, according to the kinetic data reported previously (155) and obtained
in the present study, we should have Vmax = 400 M min-1 and KM = 3.1 M against
(-)-cocaine, Vmax = 180 M min-1 and KM = 13 M against norcocaine, and V'''max =
4.55 M min-1 and K'''M = 207 M against BE when [E] = 0.07 M. It was reported that
non-specific carboxylesterase in humans and rodents is responsible for catalyzing the
hydrolysis of the methyl ester group of (-)-cocaine to BE, and the reaction follows the
simple Michaelis-Menten kinetics with KM = 116 µM (166). The human carboxylesterase
mainly exists in liver, as well as other tissues. It is known that (-)-cocaine can diffuse in
the body very rapidly to reach the equilibrium (158). Thus, it is reasonable to assume that
(-)-cocaine, BE, and norcocaine distributions in the blood and other tissues can rapidly
reach the equilibrium during the metabolic reactions. It was roughly estimated that F3 =
4.5 M min-1 and k3 = 116 µM for (-)-cocaine hydrolysis to BE, according to the
available experimental data including the enzyme activity

(167)

and the enzyme

distribution in the body (168). In our previous study, it has been estimated that F2 = 14.4
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M min-1 and k2 = 2.7 mM for the enzymatic oxidation of (-)-cocaine to norcocaine (125).
These roughly estimated kinetic parameters were used in our kinetic modeling with
various initial concentrations; our additional modeling tests revealed that kinetic
modeling using different values of the catalytic parameters would lead to the same
qualitative conclusions mentioned below.
For possible cocaine overdose treatment using an exogenous cocaine-metabolizing
enzyme, the cocaine abusers have already taken (-)-cocaine, and converted some
(-)-cocaine to BE and norcocaine before the enzyme administration. In order to know
whether E12-7 is also efficacious in hydrolysis of BE, in addition to (-)-cocaine and
norcocaine, for the cocaine overdose treatment, we performed an additional, simplified
kinetic modeling by assuming that 45% (-)-cocaine has been converted to BE, 5%
(-)-cocaine has been converted to norcocaine, and only 50% (-)-cocaine remains as
(-)-cocaine when t = 0. Depicted in Figure 3.4 are data obtained from the simplified
kinetic modeling when A(0) (the initial concentration of (-)-cocaine) = 50 μM, B(0) (the
initial concentration of BE) = 45 μM, and F(0) (the initial concentration of norcocaine)
= 5 μM. As seen in Figure 3.4A to C, in the absence of E12-7, (-)-cocaine has a half-life
(t1/2) of 98 min (t1/2 = 98 min), and t1/2 = 65 min for norcocaine and t1/2 = 318 min for BE.
As seen in Figure 3.4D to F, in the presence of 0.07 μM E12-7, both (-)-cocaine and
norcocaine are eliminated completely in less than 1 min. However, there was still a
significant amount of BE left (AUC of BE = 2270 μM·min), but the half-life of BE is
reduced significantly from 318 min to 36 min. These data qualitatively suggest that
E12-7 can be effective for cocaine overdose treatment as it can completely break down
(-)-cocaine and norcocaine, prevent (-)-cocaine from converting to BE, and
significantly decrease the half-life and AUC of BE. So, E12-7 can lower the BE
concentration in plasma through accelerating not only (-)-cocaine benzoyl ester
hydrolysis, but also BE hydrolysis.
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Figure 3.4 The modeled concentrations of (-)-cocaine, BE, and norcocaine in human
blood when the initial concentrations of (-)-cocaine, BE, and norcocaine are 50, 45, and
5 M, respectively. (A) to (C) refer to the time-dependent concentrations in the
presence of wild-type human BChE (without E12-7), whereas (D) to (F) refer to the
time-dependent concentrations in the presence of 0.07 μM E12-7. This figure came
from ref.(147).
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Figure 3.5 LC-MS/MS calibration curves for BE and ecgonine. Calibration curves
were established by calculating the ratios of the peak area for analyte to that for the
internal standard and plotting the ratio as a function of the ratio of the analyte
concentration to the internal standard. X-axis (Analyte Conc. / IS Conc.) refers to the
ratio of the analyte concentration to the corresponding internal standard concentration
(IS Conc. = 0.1 µM for each internal standard compound). Y-axis (Analyte Area / IS
Area) represents the ratio of the measured area for the analyte to that for the
corresponding internal standard. For each compound (BE or ecgonine), data were
fitted to a linear curve using the least-squares analysis with 1/x weighting. This figure
came from ref.(147).
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Figure 3.6 Metabolic profiles of BE in the presence and absence of an exogenous
enzyme E12-7 (0.15 or 5 mg/kg) in rats (n=4 for each group). (A) Time course of BE
concentration in rat blood. (B) Time course of ecgonine concentration formed from BE
in rat blood. (C) Time course of ecgonine in rat blood after IV injection of 2 mg/kg
ecgonine. (D) Time course of plasma E12-7 concentration in rat plasma after IV
injection of 5 mg/kg E12-7. p < 0.001 represents that there were statistical differences
in blood concentrations of BE and ecgonine between different experimental groups
(treated with saline or 0.15 mg/kg E12-7 or 5 mg/kg E12-7) as determined by the
two-way analysis of variance (ANOVA) tests using the SigmaPlot software (Systat
Software, San Jose, CA). This figure came from ref.(147).
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To validate the effectiveness of E12-7 in accelerating BE hydrolysis in vivo, four
groups of rats (n=4 for each group) were used in this study. The obtained calibration
curves for detecting BE and its hydrolysis product ecgonine are depicted in Figure 3.5,
and the obtained in vivo data are shown in Figure 3.6. The first three groups of rats were
injected intravenously (IV) with 0.15 mg/kg E12-7 or 5 mg/kg E12-7 or saline,
followed by IV injection of 2 mg/kg BE one minute after the enzyme/saline injection.
The dose of 0.15 mg/kg E12-7 led to an E12-7 concentration of ~3 mg/L (which is
about a half of the average concentration of the endogenous BChE in human

) in

(155)

plasma at ~2 min after IV injection of E12-7 according to our previous study (83). The
dose of 5 mg/kg resulted in a plasma E12-7 concentration between 0.45 M at 5 min
and ~0.1 M at 180 min (Figure 3.6D). The final group of rats were injected with 2
mg/kg ecgonine (metabolite of BE), instead of 2 mg/kg BE, in order to know the
elimination profile of ecgonine. For each rat, blood samples were collected at 2, 5, 10,
30, 60, 90, 120, 150, and 180 min after the BE or ecgonine injection. The collected
blood samples were analyzed by using a sensitive LC-MS/MS method to determine
the blood concentrations of BE and ecgonine. In addition, blood samples collected
from the rats injected with E12-7 were also analyzed for the E12-7 concentrations.
Statistical analysis using the two-way analysis of variance (ANOVA) method
implemented in the SigmaPlot software (Systat Software, San Jose, CA) revealed that p
< 0.001, i.e. significant differences exist in the blood concentrations of BE and
ecgonine between different experimental groups (treated with saline or 0.15 mg/kg
E12-7 or 5 mg/kg E12-7). Further, according to the two-way ANOVA with post hoc
Dunnett’s testing, the differences in the mean BE concentrations between the high-dose
group (treated with 5 mg/kg E12-7) and the control group (treated with saline) were
significant (p < 0.001), although the differences between the low-dose group (0.15
mg/kg E12-7) and the control group were insignificant (p = 0.117). So, according to the
in vivo data depicted in Figure 3.6, E12-7 dose-dependently accelerated BE hydrolysis
to ecgonine. The enzyme-accelerated BE clearance (Figure 3.6A) is consistent with the
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increased production of BE metabolite ecgonine (Figure 3.6B). In comparison with the
ecgonine elimination profile shown in Figure 3.6C, the data depicted in Figure 3.6B
revealed that ecgonine was formed continuously until BE was consumed.
3.5 Perspectives in further enzyme development for cocaine overdose treatment
This is the first identification of metabolic enzymes of BE, demonstrating that
plasma enzyme BChE is the endogenous metabolic enzyme of BE and the BChE
mutant E12-7 with significantly improved catalytic efficiency against BE compared to
wild-type BChE may be used as an exogenous enzyme to effectively accelerate BE
hydrolysis in the body for cocaine overdose treatment. Compared to RBP-8000 (the
T172R/G173Q mutant of CocE) (88, 90) under current clinical development for cocaine
overdose treatment, E12-7 is not only more efficient against cocaine

, but also

(102)

effective in hydrolyzing BE. Hence, E12-7 should be a more promising therapeutic
candidate for cocaine overdose treatment in comparison with the T172R/G173Q
mutant of CocE, although one would like to further improve the catalytic efficiency
against BE for cocaine overdose treatment.
In addition, our most recently reported study

(169)

demonstrated a novel protein

form of E12-7 (or CocH3) (see Chapter 5), denoted as CocH3-Fc or catalytic antibody
analog, which is an Fc-fused CocH3 dimer (CocH3-Fc) constructed by using CocH3 to
replace the Fab region of human immunoglobulin G1. A single dose of CocH3-Fc was
able to accelerate cocaine metabolism in rats even after 20 days and, thus, block
cocaine-induced hyperactivity and toxicity for a long period of time (48). Thus, taking all
of these together, E12-7 (or CocH3) in its Fc-fusion protein form may be used as a truly
promising therapeutic candidate for treatment of both cocaine addiction and overdose.
Further, the findings in this study provide an exciting starting point for future
efforts to rationally design and discover new BChE mutants with further improved
catalytic efficiency against BE, in addition to cocaine itself and other toxic metabolites
. A highly efficient enzyme which can efficiently convert BE to biologically

(124, 155)
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inactive metabolites is valuable for not only cocaine overdose treatment, but also BE
detoxification in environment because BE widely exists in environment worldwide (149)
including drinking water due to cocaine abuse.
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Chapter 4: A Quantitative LC-MS/MS Method for Simultaneous Determination
of Cocaine and Its Metabolites in Whole Blood

Summary: As new metabolic pathways of cocaine were recently identified, a
LC-MS/MS method was developed to simultaneously determine cocaine and nine
cocaine-related metabolites in whole blood samples. One-step solid phase extraction
was used to extract all of the ten compounds and corresponding internal standards
from blood samples. All compounds and internal standards extracted were separated
on an Atlantis T3 (100Å, 3 µm, 2.1 mm X 150 mm I.D) column and detected in
positive ion and high sensitivity mode with multiple reaction monitoring. This method
was validated for its sensitivity, linearity, specificity, accuracy, precision, recovery,
and stability. All of the ten compounds were quantifiable ranging from the lower limit
of quantification (LLOQs) of ~10 nM (1.9-3.2 ng/ml) to ~1000 nM (190-320 ng/ml)
without any interfering substance. Accuracy and precision were determined; and both
of them were within the acceptance criteria of the US FDA and European Medicines
Agency (EMA) guidelines. The recovery was above 66.7% for all compounds. Stability
tests demonstrated the stability of compounds under different storage conditions in
whole blood samples. The method was successfully applied to a pharmacokinetic study
with co-administration of cocaine and alcohol to rats.
4.1 The need for development of a LC-MS/MS method
Cocaine is one of the most reinforcing and hepatotoxic drugs, accounting for
majority of illicit drug-related ED visits in the United State

. In humans,

(170)

approximately 40% of cocaine is hydrolyzed to biologically inactive metabolite EME
by plasma enzyme BChE and liver CE-2, but more cocaine is biotransformed to BE
via hydrolysis catalyzed by CE-1, and to norcocaine via oxidization catalyzed by liver
microsomal cytochrome P450 (CYP) 3A4

. This metabolic profile of

(46, 171, 172)

cocaine is highly affected by alcohol co-consumption which commonly happens
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among cocaine users (173). Especially, alcohol decreases the hydrolysis of cocaine to
BE by inhibiting the catalytic activity of CE-1

. Meanwhile, ethanol reacts

(26, 174, 175)

with cocaine via catalysis by CE-1 to produce cocaethylene, which is further oxidized
to norcocaethylene by CYP 3A4

. With alcohol co-administration, ~34%

(26, 46, 171, 172)

(oral), ~24% (IV), or ~18% (smoked) of cocaine is converted to cocaethylene through
transesterification (173).
Among the cocaine metabolites described above, BE, norcocaine, cocaethylene,
and norcocaethylene are all physiologically/biologically active. These active
metabolites have strong physiological effects such as vasoconstrictive effects, causing
the hemodynamic changes, and producing lethality (171, 176-180). Recently, the metabolic
pathways of those toxic compounds were identified during the process of developing
therapeutic treatment for cocaine abuse. Briefly, BChE can catalyze the hydrolysis of
BE to ecgonine (ECG), norcocaine to norecgonine methyl ester (NEME),
cocaethylene to ecgonine ethyl ester (EEE), and norcocaethylene to norecgonine ethyl
ester (NEEE) (124, 125, 147, 181).
Disastrous medical and social consequences of cocaine make it a high priority to
develop an anti-cocaine medication for treatment-seeking users

. There have

(44, 45)

been extensive efforts in development of therapeutic agents for cocaine abuse (16, 47, 48,
. Although target-based, traditional pharmacodynamics

77, 83, 91, 92, 102, 104, 172, 182-186)

approaches using a small-molecule compound to treat cocaine have not yielded a truly
effective drug

, alternative approaches using biologics (vaccines, monoclonal

(77)

antibodies, and cocaine-metabolizing enzymes) have been shown some promise.
Preclinical and clinical studies indicate that biologic approaches are effective in both
blocking cocaine toxicity and reducing drug craving

.

(48, 83, 102, 104, 172, 182, 183) (91, 92)

Biologics block cocaine’s access to the central nervous system (CNS) or other acting
sites by either binding with cocaine or hydrolyzing it

, possibly resulting in a

(16, 47, 48)

significant change of cocaine’s metabolic profile. There are extensive ongoing studies
in developing highly effective medicines and, meanwhile, investigating their effects
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on the altering metabolic profiles of cocaine in the presence/absence of other
substances (e.g. alcohol) co-administrated. Therefore, it is highly desirable to develop
a thoroughly validated bio-analytical method to simultaneously determine the blood
concentrations of cocaine and related compounds.
A HPLC method with a UV detector was established in our previous studies to
characterize pharmacokinetic profiles of cocaine and cocaine-related compounds in
rats

. However, the UV method cannot be used to determine EME, ECG,

(83, 124, 125)

NEME, EEE, and NEEE due to the lack of a conjugated system in these compounds.
Several GC-MS and LC-MS/MS methods have been reported for simultaneous
determination of cocaine and its metabolites including BE, norcocaine, cocaethylene,
EME and ECG

. These methods provided great separation, sensitivity and

(187-192)

selectivity. However, none of them was developed to determine NEME, EEE, or
NEEE in whole blood. We hereby present a LC-MS/MS method combined with
one-step solid phase extraction, allowing simultaneous determination of cocaine and
all of the nine cocaine-related compounds. The method was applied to the analysis of
whole blood samples for pharmacokinetic study in rats with co-administration of
cocaine and alcohol.
4.2 Materials and methods
4.2.1 Materials
Cocaine, EME, BE, ECG, norcocaine, cocaethylene, EEE, and norcocaethylene
were provided by the National Institute of Drug Abuse (NIDA) Drug Supply Program
(Bethesda, MD). NEME and NEEE were synthesized in this study with the purity
of >99%. The isotopic corresponding internal standards (IS) including cocaine-D3,
EME-D3, BE-D3, ECG-D3, and cocaethylene-D3 were ordered from Cerilliant (Round
Rock, TX). Ethanol, paraoxon, heparin, HPLC-grade methanol, and acetonitrile were
purchased from Thermo Fisher Scientific (Waltham, MA). Formic acid was from
Sigma-Aldrich (St. Louis, MO). Drug-free blank rat whole blood was sampled from
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male Sprague–Darley rats that were ordered from Harlan (Indianapolis, IN). Mixed
cation exchange model solid phase extraction cartridges (Oasis MCX 1 cc Vac
Cartridge, 10 mg) were obtained from Waters (Milford, MA).
4.2.2 Liquid chromatographic and mass spectrometric conditions
A Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of a
DGU-20A/3R degasser, LC-20AD binary pumps, CBM-20A controller, and
SIL-20A/HT auto sampler, was used in this study. The chromatographic analysis was
carried out on an Atlantis T3 (100Å, 3 µm, 2.1 mm X 150 mm I.D) column (Waters,
Milford, MA). The mobile phase A consisted of 0.1% formic acid and mobile phase B
consisted of mobile phase A: acetonitrile (10:90, v/v). The flow rate was set at 0.2
ml/min. A 5 μl injection of each sample was loaded on to the column, separated and
eluted using the following gradient: 0% B at 0 min, hold 0% B for 5 min, then B
increased to 20% at 6 min, 40% B at 16 min, and 90% B at 18 min, hold 90% B for 4
min, 0% B at 23 min, and re-equilibrate at 0% B for 5 min. The total run time was 28
min. The column temperature was maintained at room temperature (~21oC). The auto
sampler temperature was maintained at 15oC, and the auto sampler injection needle was
washed with 200 μl mobile phase A: methanol (50:50, v/v) after each sample injection
to reduce the carryover.
The mass spectrometer, AB SCIEX tripleTOFTM 5600 (AB SCIEX, Redwood City,
CA), was run in positive ion and high sensitivity mode under the following conditions
and settings: positive ions were generated in the source using nitrogen as the source
gases. Ion source gas 1 (GS1) and 2 (GS2) were set at 25 and 35 respectively, and
curtain gas (CUR) was set at 40. Source gas temperature was set at 500oC. Ion spray
voltage floating (ISVF) was 3000 V. Compound-specific ionization parameters, ion
transition, declustering potential (DP), collision energy (CE), collision energy spread
(CES), ion release delay (IRD), and ion release width (IRW) were optimized and
summarized in Table 4.1. Analyst® TF 1.7 software (AB SCIEX, Redwood City, CA)
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was used for instrument control and data acquisition. MultiQuant™ 3.0 software (AB
SCIEX, Redwood City, CA) was used for quantitative analysis.

Table 4.1 Optimized compound-specific source parameters for electrospray ionization
Drugs
Cocaine
EME
BE
ECG
Norcocaine
NEME
Cocaethylene
EEE
Norcocaethylene
NEEE
Cocaine-D3
EME-D3
BE-D3
ECG-D3
Cocaethylene-D3

Ion transition
304.1⟶182.1
200.1⟶182.1
290.1⟶168.1
186.1⟶168.1
290.1⟶168.1
186.1⟶136.1
318.2⟶196.1
214.1⟶196.1
304.2⟶182.1
200.1⟶182.1
307.2⟶185.1
203.1⟶185.1
293.2⟶171.1
189.1⟶171.1
321.2⟶199.2

DP (V)
100
80
60
40
50
90
50
40
80
60
50
60
60
30
50

CE (eV) CES (V) IRD IRW
30
3.0
45
17
31
3.0
45
17
28
3.0
45
17
27
3.0
45
17
25
3.0
45
17
36
3.0
45
17
29
3.0
45
17
28
3.0
45
17
24
3.0
45
17
22
3.0
45
17
30
3.0
45
17
30
3.0
45
17
30
3.0
45
17
25
3.0
45
17
28
3.0
45
17

4.2.3 Treatment of blood samples for mass spectrometry
The sample extraction method used in this study was established in our previously
studied (147, 169, 181). Briefly, internal standard (IS) solution (0.1 μM for each IS) with a
volume equal to that of the whole blood was added to each blood sample. The mixture
was vortexed and then centrifuged for 15 min at 13,000 rpm; and the supernatant was
collected and mixed with 500 μl 4% formic acid. Before being loaded onto solid-phase
extraction column, Oasis MCX 1 cc Vac Cartridge, conditioned by 1 ml methanol
followed by 1 ml water, the sample was centrifuged at 13,000 rpm for 15 min. Loaded
cartridge was washed twice with 1 ml methanol, and the contents were eluted twice
with 500 μl methanol/water solution (95:5, v/v, with 7.5% ammonium hydroxide).
Eluate was evaporated to dryness at 25oC using a vacuum concentrator, reconstituted in
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74 μl 0.1% formic acid, and centrifuged at 13,000 rpm for 15 min. Supernatant was
transferred to a vial and stored refrigerated until analysis by LC-MS/MS.
4.2.4 Preparation of stock, calibration standards and quality control samples
Combined stock solution was prepared by mixing solutions of cocaine and its
metabolites with those of the corresponding deuterium-labeled IS. The final
concentration is 10 μM for each analyte, and 0.1 μM for each IS. Combined standard
solutions, prepared by diluting the combined stock solution using the IS solution (0.1
μM for each IS), with the various concentrations for each analyte and 0.1 μM for each
corresponding IS. Calibration standards were prepared by adding 74 μl different
concentrations of combined standard solutions into 174 μl blood mixture (74 μl whole
blood + 100 μl paraoxon solution) from untreated Sprague-Dawley rats. Quality control
samples were prepared in the same manner. The same method as described above was
used to extract cocaine, nine cocaine-related compounds, and all ISs.
4.2.5 Method validation
Linearity and sensitivity. The validation was performed according to the United
States (US) Food and Drug Administration (FDA) and European Medicines Agency
(EMA) guidelines (193, 194). A calibration curve was established by calculating the ratio
of the peak area for analyte to that for the internal standard and plotting the ratio as a
function of the ratio of the analyte concentration to the internal standard. The limit of
detection (LOD) was considered the lowest concentration of analyte where the
signal-noise ratio was greater than 3. The lower limit of quantification (LLQC) was
defined as the lowest concentration of analyte with accuracy < 20% of the coefficient of
variation (CV) and a precision within 20% of the nominal concentration.
Selectivity and carryover. Six sources of blank rat blood were individually
analyzed and evaluated to determine if any interfering components were more than 20%
of the LLQC for the analytes and 5% for the internal standards. Carryover was assessed
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by injection of a drug-free blank sample after a high concentration sample. Carryover in
the blank sample should be less than 20% of the LLQC for the analytes and 5% for the
internal standards.
Extraction recovery and matrix effect. Matrix effect and extraction recovery
were determined in six replicates, at LLOQ, medium, and high concentration for all
analytes. Samples were prepared in three ways as described by Liu et al. [2]: (a)
prepared in the absence of blank matrix, (b) prepared by adding analyte to blank matrix
extract, and (c), prepared by adding analyte to blank matrix prior to solid phase
extraction. The matrix effect was calculated by dividing peak area of sample b by
sample a; and the extraction recovery was calculated by dividing peak area of sample c
by sample b.
Precision and accuracy. Accuracy was expressed as the percentage of the
determined concentration to the nominal concentration of the analyte; and precision
was expressed as % CV. Intra-day accuracy and precision of this method were assessed
by analyzing in a single run of six QC samples at three levels including LLOQ, medium
QC, and high QC. For inter-day accuracy and precision, LLOQ, medium QC, and high
QC from three runs on three different days were evaluated.
Stability. The stabilities of cocaine and cocaine-related compounds in whole blood
were evaluated using low, medium, and high QC samples (n = 6 for each level). The
analyte was considered to be stable if the mean concentration at each level was within
±15% of the nominal concentration except for the LLOQ which should be within ±20%
of the nominal value. The freeze and thaw stability samples were analyzed following
four freeze-thaw cycles. The short-term stability samples were stored at room
temperature for 4 hours, and the long-term stability samples were stored at -70oC for 4
months.
4.2.6 Animal tests and sample collection
Male Sprague–Darley rats (wt) were ordered from Harlan (Indianapolis, IN), and
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housed initially as one or two rats per cage. All rats were allowed ad libitum access to
food and water and maintained on a 12 h light/12 h dark cycle, with the lights on at 8:00
a.m. at a room temperature of 21–22oC. Experiments were performed in the same
colony room in accordance with the Guide for the Care and Use of Laboratory Animals
as adopted and promulgated by the National Institutes of Health. The animal protocol
was approved by the IACUC (Institutional Animal Care and Use Committee) at the
University of Kentucky. Rats (n=10) received IP injection of 1 g/kg alcohol followed by
cocaine administration (60 mg/kg, IP) 30 min after the injection of alcohol. Blood
samples (5075 μl) were collected into a heparin-treated capillary tube at 5, 10, 15,20,
30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480, and 600 min after the cocaine
administration, and mixed with 100 µl paraoxon solution (250 μM paraoxon, 10 U/ml
heparin) immediately. Blood samples were stored at −80oC until sample extraction.
4.3 Method development
The optimization of sample preparation was performed with rat whole blood. Both
perchloric acid and formic acid were tested for the sample acidification. With the
treatment of perchloric acid, majority of protein in blood samples was precipitated, but
the extraction recovery rates of analytes were significantly lower than those with the
treatment of formic acid. Thus, the formic acid was chosen to acidify the sample.
Various concentrations of formic acid with different volumes were also tested to clean
up the blood samples before being loaded on the SPE column. Eventually, 4% formic
acid with a volume 500 μl was selected.
A great challenge of this LC-MS/MS method is to separate three pairs of
compounds: cocaine and norcocaethylene, norcocaine and BE, and ECG and NEME.
Both compounds within each pair have exactly the same m/z, and very similar
physicochemical properties and ion transition. Unqualified separation within the pair
makes it extremely difficult to avoid the interference from each other. To solve this
problem, the liquid chromatography method was modified according to the
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well-established method by Dr. Imbert

. The aqueous phase (phase A) of 2 mM

(195)

ammonium formate, pH 3.0, was replaced by 0.1% formic acid. The gradient program
was also adjusted with 0% B for the first 5 min separation, and longer holding of the
initial condition before the next injection.
Although the liquid chromatography method was optimized to get the good
separation, the retention time of ECG (3.27 min) is still close to that of NEME (3.04
min). In order to further avoid the interference between ECG and NEME,
compound-specific source parameters for electrospray ionization were optimized to
generate fragment ion of ECG mainly at m/z 168.1 and fragment ion of NEME mainly
at m/z 136.1.
4.4 Method validation
Selectivity and carryover. Six blank matrix samples from different sources were
analyzed to access the selectivity. There was no endogenous interference observed. The
auto sampler injection needle was washed with 200 μl mobile phase A: methanol
(50:50, v/v) after each sample injection to reduce carryover. Only slight carryover
effects (less than 20% of the LLQCs for the analytes and 5% for the internal standards)
in the blank samples were observed. To further avoid the carryover, a 0.1% formic acid
sample was always injected following the samples.
Linearity and sensitivity. LODs, LLOQs, and regression diagnostics of all
analytes were reported in Table 4.2. The LODs and LLOQs for this method ranged
from 0.2 to 0.9 ng/ml and 1.9 to 3.2 ng/ml, respectively, for all the substrates in whole
blood samples. The calibration curve was linear over the concentration range of LLOQ
to 200/300 ng/ml, with the correlation coefficients (r) > 0.99.

62

Table 4.2 Linearity, regression diagnostics, LODs, and LLOQs
Compound

Internal standard

Slope

Cocaine
EME
BE
ECG
Norcocaine
NEME
Cocaethylene
EEE
Norcocaethylene
NEEE

Cocaine-D3
0.7279
EME-D3
0.8994
BE-D3
0.6905
ECG-D3
0.6526
Coc-D3
0.3274
Coc-D3
0.0816
Cocaethylene-D3 0.8920
Coc-D3
0.5001
Coc-D3
0.4590
Coc-D3
0.1131

Intercept

r

0.0319
0.0352
0.0562
0.0263
0.0054
0.0044
0.0178
0.0030
0.0061
0.0026

0.9973
0.9984
0.9969
0.9965
0.9974
0.9942
0.9986
0.9972
0.9974
0.9966

LOD
LLOQ
(ng/ml) (ng/ml)
0.9
3.0
0.6
2.0
0.9
2.9
0.6
1.9
0.3
2.9
0.2
1.9
0.3
3.2
0.2
2.1
0.3
3.0
0.2
2.0

Extraction recovery and matrix effect. Extraction recovery and matrix effect
values at low, medium, and high concentrations are reported in Table 4.3. Significant
ion suppression was observed for EME at low, medium, and high concentrations, with
matrix effects of 23.2%, 31.2%, and 34.6% respectively. Although the similar ion
suppression for ECG in the blood matrix was reported (192), there was no such strong ion
suppression for ECG observed in this study, with the matrix effects of ECG 67.6%,
70.2 %, and 71.8% at low, medium, and high concentrations, respectively. The matrix
effects of other eight substrates ranged from 52.1% to 104.1% at low concentration,
from 57.7% to 88.3% at medium concentration, and from 59% to 84.7% at high
concentration. The one-step solid phase extraction yielded good recoveries for all of the
ten analytes, with the extraction recovery rates ranging from 66.7% to 96.2 at low
concentration, from 82.9% to 113.9% at medium concentration, and from 76.8% to
96.7 at high concentration.
Precision and accuracy. Intra- and inter-day precision and accuracy were
evaluated by analyzing QC samples (n = 6) at the low, medium, and high concentrations.
The accuracy and precision data are summarized in Table 4.4. The intra-day precision
(%CV) was 12.5% or less, and the inter-day precision was 13.6% or less. The intra-day
accuracy was within ±13.6, and the inter-day accuracy was within ±15.0. According to
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the US FDA and EMA guidelines (193, 194), the bias values for intra- and inter-accuracy
should be within 15% of the nominal values for QC samples, except for the LLOQ
which should be within 20% of nominal concentrations, and the CV values for intraand inter-precision should not be larger than 15% for QC samples, except for the LLOQ
which should not exceed 20%. Therefore, the accuracy and precision values for the
intra- and inter-studies of all cocaine and the nine related compounds are acceptable.
Stability. The stability testing is very important to evaluate the stability of all
substrates during the sample collection and handling. The stability of analytes was
evaluated at three concentrations after long-term and short-term storage, and after four
freeze-thaw cycles. Results of stability testing are shown in Table 4.5. The mean
concentration of each compound (cocaine or metabolite) at each level was always
within 15% of the nominal concentration for all stability tests. These results indicate
that all compounds were stable at room temperature for at least four hours and at -80oC
for at least four months; and the QC samples of all compounds were not affected by the
four freeze-thaw cycles.
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Table 4.3 Matrix effect (ME) and extraction recovery at low, medium, and high concentrations in rat whole blood
Compound
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Cocaine
EME
BE
ECG
Norcocaine
NEME
Cocaethylene
EEE
Norcocaethylene
NEEE

Low concentration
ME (%)
ER (%)
62.3 ± 8.3
78.8 ± 19.2
23.2 ± 3.4
87 ± 8.6
104.1 ± 7.4
96.2 ± 6.8
67.6 ± 6.5
95.1 ± 18.9
82.1 ± 6.1
73.1 ± 3.1
52.1 ± 5.2
66.7 ± 11.3
58.5 ± 4.8
73.9 ± 4.9
75.6 ± 7.7
81.3 ± 10.2
79.9 ± 10.6
69.1 ± 4.7
84.3 ± 13.2
86.5 ± 11.5

Medium concentration
ME (%)
ER (%)
82.2 ± 3.8
97.1 ± 7.4
31.2 ± 1.8
82.9 ± 5.6
82.8 ± 4.5
112.5 ± 9.3
70.2 ± 4.7
113.9 ± 3.8
88.3 ± 4.8
92.2 ± 8.3
57.7 ± 5.2
98 ± 6.9
72.3 ± 2.6
90.3 ± 2.9
82.6 ± 6.7
103.7 ± 8.2
77.7 ± 5.7
92.8 ± 2.8
81.6 ± 10.1
100.3 ± 13.8

High concentration
ME (%)
ER (%)
81.8 ± 3.2
77.8 ± 8.2
34.6 ± 2.3
87.9 ± 3.4
65.5 ± 2.8
87.9 ± 3.4
71.8 ± 3.7
90.8 ± 3.5
83.8 ± 4.4
83.9 ± 8.9
59 ± 4.3
91.5 ± 5.0
75.3 ± 4.1
76.8 ± 6.3
84.7 ± 4.2
86.4 ± 4.5
75.9 ± 4.3
76.8 ± 8.4
81.8 ± 10.9
96.7 ± 9.1

IS
ME (%)
84.2 ± 4.9
23.6 ± 1.4
87.8 ± 4.8
91.2 ± 5.6
84.2 ± 4.9
84.2 ± 4.9
59.7 ± 4.8
84.2 ± 4.9
84.2 ± 4.9
84.2 ± 4.9

ER (%)
73.9 ± 3.0
79.4 ± 5.6
81.4 ± 5.2
84.2 ± 7.5
73.9 ± 3.0
73.9 ± 3.0
72.9 ± 4.3
73.9 ± 3.0
73.9 ± 3.0
73.9 ± 3.0

Table 4.4 The intra- and inter-day precision and accuracy of the LC-MS/MS method used to quantify cocaine and its related compound in
whole blood samples
Drug
L
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Cocaine
EME
BE
ECG
Norcocaine
NEME
Cocaethylene
EEE
Norcocaethylene
NEEE

CV
(%)
10.3
8.0
11.1
12.5
2.5
9.8
4.1
8.2
2.2
5.9

Bias
(%)
-11.1
-2.9
-13.6
9.7
11.8
11.9
-11.6
5.7
13.5
12.5

Intra-day
M
CV
Bias
(%)
(%)
7.1
4.5
4.0
-0.4
5.9
-0.7
10.9
-3.7
2.9
2.3
4.2
-6.4
2.0
1.7
3.2
1.1
4.7
3.3
3.5
-4.1

H
CV
(%)
4.0
3.5
7.1
5.2
7.9
5.9
5.8
3.4
7.4
6.0

L
Bias
(%)
0.3
-3.2
-4.4
1.2
9.9
10.2
-1.1
5.6
1.2
7.2

CV
(%)
10.8
7.8
0.7
6.9
0.9
13.6
1.9
7.7
1.2
11.9

Bias
(%)
-13.3
-8.8
-14.8
3.5
12.8
8.5
-10.4
-1.1
15.0
11.4

Inter-day
M
CV
Bias
(%)
(%)
2.0
2.2
3.2
3.3
1.1
0.6
2.9
-0.5
1.1
3.4
7.0
-11.1
0.5
1.2
6.4
-5.9
1.2
1.8
1.6
-5.8

H
CV
(%)
0.6
2.7
1.9
4.3
1.6
2.3
1.1
4.3
1.4
0.6

Bias
(%)
0.9
-0.2
-3.2
1.7
11.5
12.6
-2.3
10.1
2.9
7.8

Table 4.5 Stability of analytes in whole blood samples
Drug
Cocaine

Stability
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Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
EME
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
BE
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
ECG
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
Norcocaine Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
NEME
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)

Low concentration
CV (%)
Bias (%)
15.0
2.8
12.4
2.3
17.7
-0.4
19.8
2.1
15.4
-9.6
6.9
-3.1
10.7
-0.9
13.6
-0.5
9.3
-1.4
14.9
3.5
9.5
-1.5
12.7
-4.9
8.2
-1.0
8.4
-1.1
3.3
-2.9
12.4
-12.8
11.3
-14.3
10.0
-13.0

Medium concentration
CV (%)
Bias (%)
9.8
-0.7
6.7
0.3
9.9
3.1
9.8
4.2
4.7
5.9
8.6
6.3
7.2
5.5
8.6
0.7
5.1
2.2
9.4
10.2
4.8
7.6
9.7
10.7
11.7
-0.2
4.6
3.5
6.4
2.2
6.6
-5.4
5.7
-1.5
4.0
-1.7

High concentration
CV (%)
Bias (%)
4.5
-4.7
4.8
-6.7
5.7
-3.1
5.9
4.0
6.9
0.3
4.6
3.5
7.9
3.4
6.1
1.7
6.3
3.8
6.9
2.6
10.4
3.6
6.5
3.8
3.2
-1.2
7.2
0.6
4.2
-1.4
9.4
0.1
10.6
-2.2
10.8
-8.7

Table 4.5 (continued) Stability of analytes in whole blood samples
Drug
Cocaethylene

Stability
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Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
EEE
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
Norcocaethylene Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)
NEEE
Freeze-thaw (4 cycles)
Bench top (4 hours)
Long-term (-70oC, 4 months)

Low concentration
CV (%)
Bias (%)
4.7
0.7
4.2
1.7
5.4
3.7
7.0
-3.2
8.5
1.2
6.2
-2.2
5.9
0.1
3.2
-0.2
5.1
-1.0
4.9
1.2
8.6
1.4
10.1
-1.3

Medium concentration
CV (%)
Bias (%)
4.8
-3.7
4.5
-2.1
3.9
-1.8
9.4
-9.3
4.4
-4.4
8.8
-5.2
7.2
-4.4
7.2
-0.9
7.7
-1.3
13.3
3.3
5.1
2.4
8.1
-0.2

High concentration
CV (%)
Bias (%)
3.2
-4.1
7.6
0.2
1.4
-0.6
7.7
9.4
8.3
6.8
13.5
-5.2
5.4
-6.4
4.1
-2.2
3.6
2.8
4.7
6.5
12.1
3.7
9.0
-11.9

4.5 Application of the method
The validated method was used to quantify the concentrations of cocaine and the
nine related compounds in blood samples collected in a pharmacokinetic study with
co-administration of cocaine and alcohol to rats. The mean blood concentration
time-course profiles for cocaine and its metabolites after the IP injection of 60 mg/kg
cocaine (30 min after the injection of 1 g/kg alcohol) to rats are depicted in Figure 4.1.
Cocaine reached its highest concentration of 2400 ng/ml 20 min after the injection of
cocaine, and then slowly fell over the 600-min period. Although part of cocaine was
hydrolyzed to biological inactive product EME, majority of cocaine was converted to
physiologically/biologically

active

metabolites,

including

BE,

norcocaine,

cocaethylene, and norcocaethylene. These active metabolites were further metabolized
to compounds with no or little physiological effects

(125, 147, 196)

such as ECG and EEE

by the endogenous enzymes, but their concentrations fell very slowly.

Figure 4.1 Metabolic profiles of cocaine in the presence of alcohol in rats. Rats (n=10)
were injected (IP) with 1 g/kg alcohol 30 min before the IP injection of 60 mg/kg
cocaine.
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4.6 Potential applications of the developed method to future studies
We have successfully developed a simple and rapid LC-MS/MS method combined
with one-step solid phase extraction to simultaneously determine the concentrations of
cocaine, EME, BE, ECG, norcocaine, NEME, cocaethylene, EEE, norcocaethylene,
and NEEE in the rat blood samples. Great specificity, sensitivity, linearity, recovery,
accuracy, precision, and stability of the method have been well demonstrated. With a
successful application to a pharmacokinetic study in rats with co-administration of
cocaine and alcohol, this method will be valuable for further studies that aim to
characterize anti-cocaine therapeutic agents and their effects on metabolic profiles of
cocaine in the presence/absence of alcohol.
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Chapter 5：Long-acting Cocaine Hydrolase for Addiction Therapy

Summary: In the investigation described in this chapter, we demonstrate a novel
CocH form, catalytic antibody analog, which is an Fc-fused CocH dimer (CocH-Fc)
constructed by using CocH to replace the Fab region of human immunoglobulin G1.
The CocH-Fc has not only a high catalytic efficiency against cocaine, but also a
considerably longer biological half-life (e.g. ~107 hours in rats) like an antibody. A
single dose of CocH-Fc was able to accelerate cocaine metabolism in rats even after 20
days and, thus, block cocaine-induced hyperactivity and toxicity for a long period of
time. In consideration of the general observation that the biological half-life of a protein
drug in humans is significantly longer than that in rodents, the CocH-Fc reported in this
study could allow dosing once every 2-4 weeks, or longer for cocaine addiction
treatment in humans. The main results described in this chapter have been published
.

(48)

5.1 Cocaine hydrolase for cocaine addiction and its biological half-life
Preclinical and clinical data have demonstrated that these CocHs are safe for use in
humans and effective for accelerating cocaine metabolism. However, the actual
therapeutic use of a CocH in cocaine addiction treatment is limited by the short
biological half-life (e.g. 8 hours or shorter in rats) of the CocH. While TV-1380 (Figure
5.1 B) has been proven safe and effective for use in animals and humans (91, 92), its
actual therapeutic value for cocaine addiction treatment is still limited by the
moderate biological half-life which is ~8 hr in rats (86) or 43-77 hr in humans (91). In
addition, our more recently designed and discovered CocHs

(102-104)

are significantly

more active against (-)-cocaine compared to TV-1380. It is highly desired to further
engineer a more active CocH with a biological half-life longer than TV-1380.
Our current enzyme engineering design strategy is based on the observation that an
antibody (Ab), like human immunoglobulin G (IgG), has a very long biological
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half-life, because the Fc region of IgG can bind with neonatal Fc receptor (FcRn) in the
acidic environment of the endosome, and is later transported to the cell surface where
upon exposure to a neutral pH IgG is released back to the main bloodstream

. In

(197)

comparison, a recombinant enzyme such as BChE usually has a very short biological
half-life, and an antibody usually has no catalytic activity. Using a stable analog of
transition state for cocaine hydrolysis, Landry et al. (198) successfully generated the first
anti-cocaine catalytic antibody (CAb). Further effort generated the most active
anti-cocaine CAb (Figure 5.1C), known as 15A10 (kcat = 2.3 min-1 and KM = 220 µM)
, whose catalytic activity is still significantly lower than that of wild-type BChE

(159, 160)

against (-)-cocaine. It has been difficult to further improve the CAb activity because a
CAb, unlike an enzyme, can only help to stabilize the transition state for the
non-enzymatic cocaine hydrolysis; there is no covalent bond formation or breaking
between the substrate and CAb during the reaction process in light of a mechanistic
study (150).
We aimed to design a long-acting CocH form which has both the long biological
half-life of an antibody and the high catalytic activity of a CocH against (-)-cocaine. For
this purpose, starting from human IgG1 (dimer) which has both the Fc region (constant)
and Fab region (variable) as seen in Figure 5.1C, we may replace the Fab region by a
CocH for each subunit of the dimeric IgG1 to construct a catalytic antibody analog.
Technically, the C-terminus of CocH3 (the A199S/F227A/S287G/A328W/Y332G
mutant

(102)

of human BChE, full-length (FL) or truncated after amino acid #529 to

delete the tetramerization domain) was fused with the N-terminus of the hinge region
linked with Fc. CocH3 has a significantly higher catalytic efficiency (102) than CocH1 or
TV-1380 against (-)-cocaine. The obtained dimeric CocH3-Fc fusion enzyme depicted
in Figure 5.1D is highly efficient for cocaine hydrolysis. Obviously, the CocH3-Fc is
not, but structurally similar to, antibody IgG1, containing Fc which can bind with FcRn
in the acidic environment to prolong the biological half-life. Further, possible mutations
on the Fc region of CocH3-Fc were also examined in order for the CocH3-Fc to have
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the longest possible biological half-life. Various CocH3-Fc forms including Fc mutants
were proposed, prepared, and tested for their actual in vitro and in vivo profiles. In
addition, Albu-CocH1 or TV-1380 was also prepared and tested for comparison. As
shown below, the CocH3-Fc optimized, indeed, has not only a significantly higher
catalytic activity against cocaine, but also a much longer biological half-life compared
to TV-1380.

Figure 5.1 Protein structures and their catalytic parameters for cocaine hydrolysis. (A)
Human BChE; (B) Albu-CocH1 (or TV-1380); (C) CAb 15A10; and (D) CocH3-Fc.
This figure came from ref.(48).
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5.2 Materials and methods
5.2.1 Materials
The cDNAs for CocH1 (the A199S/S287G/A328W/Y332G mutant of human
BChE) and CocH3 (the A199S/F227A/S287G/A328W/Y332G mutant of human BChE)
containing N-terminal signal were generated in our previous studies

.

(89, 102)

pFUSE-hIgG1-Fc2 plasmid was purchased from InvivoGen (San Diego, CA). The
cDNA (Clone ID: HsCD00005810) for human serum albumin (HSA) was obtained
from DF/HCC DNA Resource Core (Boston, MA). Protein expression vector
pCMV-MCS was ordered from Agilent (Santa Clara, CA), and pCSC-SP-PW lentiviral
vector (plasmid 12335), pMDLg/pRRE (plasmid 12251), pRSV-Rev (plasmid 12253),
and pCMV-VSV-G (plasmids 8454) were obtained from Addgene (Cambridge, MA).
Phusion DNA polymerase, restriction endonucleases, T4 DNA ligase were ordered
from New England Biolabs (Ipswich, MA). DpnI endonuclease was obtained from
Thermo Fisher Scientific (Waltham, MA). All oligonucleotides were synthesized by
Eurofins MWG Operon (Huntsville, AL). Chinese Hamster Ovary-suspension (CHO-S)
cells, Human Embryonic Kidney (HEK)-293FT, FreeStyleTM CHO Expression
Medium, HT Supplement, L-glutamine, Dulbecco’s Modified Eagle’s Medium
(DMEM), Fetal Bovine Serum (FBS), 4-12% Tris-Glycine Mini Protein Gel, and
SimpleBlue SafeStain were from Invitrogen (Grand Island, NY). TransIT-PRO®
Transfection Kit was obtained from Mirus (Madison, WI). The rmp Protein A
Sepharose Fast Flow was purchased from GE Healthcare Life Sciences (Pittsburgh,
PA). Centrifugal Filter Units were from Millpore (Billerica, MA). (−)-Cocaine was
provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program
(Bethesda, MD); and [3H](−)-Cocaine (50 Ci/mmol) was ordered from PerkinElmer
(Waltham, Massachusetts).
Sprague-Darley rats (200–250 g) and CD-1 mice (25–30 g) were ordered from
Harlan (Harlan, Indianapolis, IN). All other chemicals were purchased from Thermo
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Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO).
5.2.2 Expression plasmids construction
With specific base-pair alterations, site-directed mutagenesis was performed to
obtain

the

cDNAs

for

A1Q/C6S/C12S/C15S/P24S

Fc(WT)

(i.e.

mutant

wild-type
Fc),

Fc),

Fc(M1)

Fc(M2)

(i.e.

(i.e.

the
the

A1V/E58Q/E69Q/E80Q/D98N/N101D/D142E/L144M mutant Fc), and Fc(M3) of
human IgG1 using pFUSE-hIgG1-Fc2 plasmid as the template

. Five expression

(199)

plasmids, pCMV-CocH3-Fc(WT), pCMV-CocH3-Fc(M1), pCMV-CocH3-Fc(M2),
pCMV-CocH3-Fc(M3), and pCMV-CocH3(FL)-Fc(M3), were constructed. Each
plasmid contains a sequence encoding native BChE signal peptide followed by CocH3
(truncated or full length) linked to the N-terminal of Fc (WT or mutant). To fuse CocH3
to Fc, overlap extension polymerase chain reaction (PCR) with Phusion DNA
polymerase was used. Primers (4 primers for each construction) used for plasmid
construction were listed in Table 5.1. Primers 1 and 2 were used to amplify CocH3 with
N-terminal signal peptide using pRc/CMV-CocH3 as template; primers 3 and 4 were
used to amplify Fc using corresponding Fc cDNA as template. Once two DNA
fragments were obtained, they were fused together by using another PCR reaction with
primers for the far ends (primers 1 and 4). Then the PCR product was digested with
restrict endonucleases, Hind III and Bgl II, and was ligated to pCMV-MCS expression
vector using T4 DNA ligase. The same method was used to construct plasmids
pCSC-CocH3-Fc(M3) and pCSC-Albu-CocH1 for large-scale protein production as
well.
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Table 5.1 Primers for plasmids construction. This table came from ref. (48).
Construction
pCMV-CocH3(FL)-Fc(
M3)

Primer
name
Primer 1
Primer 2
Primer 3
Primer 4

pCMV-CocH3-Fc(WT)
pCMV-CocH3-Fc(M1)
pCMV-CocH3-Fc(M2)
pCMV-CocH3-Fc(M3)

Primer 1
Primer 2
Primer 3
Primer 4

pCSC-CocH3-Fc(M3)

Primer 1
Primer 2
Primer 3
Primer 4

pCSC-Albu-CocH1

Primer 1
Primer 2
Primer 3
Primer 4

Primer sequence
CCCAAGCTTGGGAAGCCACCATGGATAGC
AAAGTCACAAT
GCAGGACTTAGGCTCCACGAGACCCACAC
AACTTTCTTTCTTGCTAG
TCTCGTGGAGCCTAAGTCCTGCGACAAAA
CTCACACATGCCCACCGTGCC
GGAAGATCTTCATTTACCCGGAGACAGGG
AGAG
CCCAAGCTTGGGAAGCCACCATGGATAGC
AAAGTCACAAT
GCAGGACTTAGGCTCCACGACTTTTGGAA
AAAATGATGTCCAGAAT
AGTCGTGGAGCCTAAGTCCTGCGACAAA
ACTCACACATGCCCACCGTGCC
GGAAGATCTTCATTTACCCGGAGACAGGG
AGAG
CCCGGATCCGGGAAGCCACCATGGATAGC
AAAGTCACAAT
ACTCTTGTGTGCATCGACTTTTGGAAAAA
ATGATGTCCAGAA
CATTTTTTCCAAAAGTCGATGCACACAAG
AGTGAGGTTGCTC
GGAGGGCCCTCATTTACCCGGAGACAGGG
AGAG
CCCGGATCCGGGAAGCCACCATGGATAGC
AAAGTCACAAT
ACTCTTGTGTGCATCGACTTTTGGAAAAA
ATGATGTCCAGAA
CATTTTTTCCAAAAGTCGATGCACACAAG
AGTGAGGTTGCTC
GGACTCGAGTTATAAGCCTAAGGCAGCTT
GACTTG
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5.2.3 Protein expression and purification in small-scale
CHO-S cells, incubated at 37°C in a humidified atmosphere containing 8% CO2,
were transfected with plasmids encoding the proteins using TransIT-PRO®
Transfection Kit once cells had grown to a density of 1.0 × 106 cells/ml. The culture
medium (FreeStyle™ CHO Expression Medium with 8 mM L-glutamine) was
harvested 7 days after transfection. Secreted enzyme in the culture medium was
purified by using protein A affinity chromatography. Pre-equilibrated rmp Protein A
Sepharose Fast Flow was added into cell-free medium, and incubated overnight with
occasional stirring; then packed the suspension in a column. After washing the column
with 20 mM Tris-HCl, pH 7.4 until OD280 < 0.02, protein was eluted by pH and salt
concentration adjustment. The eluate was dialyzed in storage buffer (50 mM HPEPS,
20% Sorbitol, 1 M Glycine, pH 7.4) by Millipore Centrifugal Filter Units. This whole
purification process was carried out in cold room at 6°C. The purified protein was
stored at −80°C before enzyme activity tests and in vivo studies.
5.2.4 Protein expression and purification in large-scale
A lentivirus-based method described in our previous report

(83)

was performed to

generate a high-efficient stable cell line expressing CocH3-Fc(M3). Briefly, to package
the lentivirus particles carrying the gene of CocH3-Fc(M3), lentivirus was produced by
co-transfecting

pCSC-CocH3-Fc(M3)

plasmid

with

the

packaging

vectors

(pMDLg/pRRE and pRSV-Rev) and envelope plasmid (pCMV-VSV-G) into
HEK-293FT cells by lipofection. The packaged lentivirus particles were transfected to
CHO-S cells. After lentiviral transductions, infected cells were allowed to recover from
the infection for 2 or more days, and transferred to a shake flask for further culture. The
obtained stable CHO-S cell pool was kept frozen before being used for large-scale
protein production.
The large-scale protein production was performed in an agitated bioreactor
BioFlo/CelliGen 115 (Eppendorf, Hauppauge, NY). Before being transferred into the
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bioreactor, cells grew at 37oC in shake flasks till to designated volume and density. On
the day of transferring, cells in shake flasks were centrifuged at 1500 rpm for 5 minutes
at room temperature, resuspended in fresh culture medium, and transferred into the
bioreactor. CO2/air gas overlay was set such that the pH of cell culture medium was
maintained at 7.0-8.0. The bioreactor was run in a batch model with a temperature of
32oC. After 9 days, the culture medium was harvested and the protein was purified.
CocH3-Fc(M3) was purified by using the aforementioned protein A affinity
chromatography which was performed on ÄKTA avant 150 system (GE Healthcare
Life Sciences, Pittsburgh, PA). The purified protein was dialyzed in storage buffer, and
stored at −80°C.
5.2.5 Electrophoresis
Purified CocH3-Fc(M3) was analyzed by SDS-PAGE electrophoresis. Two protein
samples, protein in its native state and protein in a denatured state, were loaded in a
4-12% Tris-Glycine Mini Protein Gel. In order to break up quaternary protein structure,
protein sample was mixed with SDS-loading buffer, heated at 95oC for 10 minutes in
the presence of a reducing agent, dithiothreitol (DTT). Electrophoresis was run at 100
volt for 2 hours. The protein gel was stained with SimpleBlue SafeStain.
5.2.6 In vitro activity test against (−)-cocaine
A radiometric assay which was used in our previous studies (102, 104) was used to test
catalytic activities of enzymes against (−)-cocaine. Briefly, 150 μl enzyme solution
(100 mM phosphate buffer, pH 7.4) was added to 50 μl varying concentrations of
[3H]-labeled (−)-cocaine, denoted as [3H](−)-cocaine (with 3H labeled on the benzene
ring). The reaction was stopped by adding 200 μl 0.1 M HCl, which neutralized the
liberated benzoic acid while ensuring a positive charge on the residual (−)-cocaine.
[3H]Benzoic acid was extracted by 1 ml of toluene and measured by scintillation
counting.

All

measurements

were
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performed

at

25oC.

Substrate

concentration-dependent data were analyzed using standard Michaelis-Menten kinetics
so that the catalytic parameters (kcat and KM) were determined.
5.2.7 Determination of biological half-lives in rats
Rats were used with the Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the National Institutes of Health. The experimental
protocols were approved by the IACUC (Institutional Animal Care and Use Committee)
at University of Kentucky. Rats were injected with purified protein via tail vein (0.06,
0.2 or 0.6 mg/kg for CocH3-Fc(M3); 0.06 or 5 mg/kg for Albu-CocH1; and 0.06 mg/kg
for all other CocH3-Fc protein forms). Blood samples were taken from saphenous vein
puncture using a needle. Approximately 50-100 µl blood was collected into a
heparin-treated capillary tube at various time points after enzyme administration.
Collected blood samples were centrifuged for 15 min at a speed of 5000 g to separate
the plasma, which was kept at 4oC before analysis. Radiometric assay using 100 μM
(−)-cocaine was used to measure the enzyme concentration in plasma. The
time-dependent enzyme concentrations ([E]t) were fitted to a well-known
double-exponential equation

(200)

k1t

by GraphPad Prism 5: ( [E]t  Ae

 Bek2t ) which

accounts for both the enzyme distribution process (the fast phase, associated with k1)
and elimination process (the slow phase, associated with k2). The half-life (t1/2)
associated with the enzyme elimination rate constant k2 is known as the elimination
half-life or biological half-life.
5.2.8 Characterization of cocaine clearance accelerated by CocH3-Fc(M3)
Four rats received saline (IV) before injection of (−)-cocaine (5 mg/kg, IV), and
other four rats received enzyme CocH3-Fc(M3) (0.2 mg/kg, IV) on Day 0, followed by
(−)-cocaine administration (5 mg/kg, IV) on Days 8, 11, 14, and 20 after the
CocH3-Fc(M3) injection. Blood samples (50-100 μl) were collected from saphenous
vein into a heparin-treated capillary tube at 2, 5, 10, 15, 30, and 60 minutes after the
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(−)-cocaine administration, and mixed with 100 µl of 25 µM paraoxon (which
inactivates the enzymes) immediately. Blood samples were stored at −80oC until
analysis by using an HPLC. To assay the (−)-cocaine and benzoic acid (the product of
cocaine hydrolysis by the enzyme) concentrations in the blood samples, frozen blood
samples were thawed on ice for more than 3 hours. Then 150 µl mobile phase (76% 0.1%
trifluoroacetic acid and 24% acetonitrile) and 50 µl 7% HClO4 were added to each
sample. The extraction mixture was vortex mixed for 1 minute, then centrifuged at 4oC
for 15 minutes at 13,200 rpm. The supernatant was decanted into a 1.5 mL tube, labeled
and stored at –80°C until analysis by HPLC. The chromatographic analysis was carried
out on a Gemini® 5 µm C18 column (Phenomenex, Torrance, CA), using a mobile
phase at a flow rate of 1 ml/min. (−)-cocaine fluorescence was monitored at 315 nm
while exciting at 230 nm (83, 201), and benzoic acid absorbance was monitored at 230 nm.
Chromatographic system used is composed a Waters 1525 binary HPLC pump, a 717
plus antosampler, a 2487 dual λ absorbance detector, and a 2475 multi λ fluorescence
detector (Waters, Milford, MA).
5.2.9 Locomotor activity assay
The effects of CocH3-Fc(M3) on cocaine-induced hyperactivity was evaluated by
using a video-tracking system at the University of Kentucky’s Rodent Behavior Core.
Mice received a single dose of CocH3-Fc(M3) (0.2 or 2 mg/kg, IV) or saline, followed
by multiple doses of cocaine (15 mg/kg, IV) or saline after 1 hour, 1, 3, 5, 7, 9, 11, 13
and 15 days. Before cocaine or saline administration, mice were allowed to acclimate to
the test chambers for 1 h. The total distance traveled during the last half hour, which
was collected in 5-min bins, was used as the basal level. After cocaine or saline
administration, mice were immediately returned to the test chamber for the remaining 1
hour of the session for activity monitoring. The locomotor tests were performed in high
density, non-porous plastic chambers measuring 50 cm (L) × 50 cm (W) × 38 cm (H) in
a light- and sound-attenuating behavioral test enclosure (San Diego Instruments, San
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Diego, CA). Cumulative distance traveled was recorded by EthoVision XT video
tracking system (Noldus Information Technology, Wageningen, Netherlands) to
represent the locomotor activity.
5.2.10 Protection study in mice
Cocaine-induced acute toxicity was characterized in this study by the occurrence of
convulsions. Cocaine-induced convulsion was defined as loss of righting posture for at
least 5 seconds with the simultaneous presence of clonic limb movements

. Mice

(202)

received a single dose of CocH3-Fc(M3) (2 mg/kg, IV) or saline (IV) on Day 0,
followed by daily dosing of cocaine (100 mg/kg, IP) starting on Day 4 until the
occurrence of convulsion for a given mouse. Following cocaine administration, mice
were immediately placed in containers for observation. The presence or absence of a
convulsion was recorded for 60 min following cocaine administration (102).
5.3 Optimization of the CocH3-Fc entity
Key in vivo data obtained are depicted in Figures 5.2, 5.4, 5.7, 5.8, 5.9, 5.10, and
5.11. All pharmacokinetic (PK) data depicted in Figures 5.2, 5.4, 5.7, and 5.8 were
based on intravenous (IV) injection of the enzymes in rats. The PK data reveal that a
CocH3-Fc form with the truncated CocH3 (without the tetramerization domain) has a
much longer biological half-life (with t1/2 up to ~107 hours) compared to that (t1/2 = ~18
hours) of the corresponding CocH3-Fc containing the full-length CocH3, denoted as
CocH3(FL) in Figure 5.2, with a given Fc region. Notably, the only difference between
CocH3(FL) and CocH3 is that CocH3(FL) has the extra 45 amino-acid residues (#530
to #574, an -helix)

(203)

on the C-terminus. Compared to the CocH3-Fc structure,

CocH3(FL)-Fc has an extra 45 amino-acid residues between CocH3 and Fc. These 45
residues increase the length of the linker between CocH3 and Fc. Due to the existence
of the longer linker, the CocH3 region is far away from the Fc region in CocH3(FL)-Fc
as shown in Figure 5.3. The longer linker may be proteolyzed more easily because it is
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flexible and, thus, CocH3(FL)-Fc has a shorter biological half-life than CocH3-Fc. The
CocH3-Fc forms to be discussed below will be only those with the same CocH3 region,
i.e. the truncated CocH3.
To optimize the Fc region of the CocH3-Fc, we tested the use of wild-type Fc,
denoted as Fc(WT), and a triple mutant (i.e. A1V/D142E/L144M) denoted as Fc(M3).
In addition, we also tested the use of known Fc mutants, denoted as Fc(M1)

(204)

and

Fc(M2) (205) here for convenience (see Methods section for the detail), that have been
used to significantly prolong the half-lives of other types of therapeutic proteins
(abatacept

(204)

and alefacept

). As seen in Figure 5.4, CocH3-Fc(M3) showed the

(205)

longest biological half-life (t1/2 = ~107 hours) in rats within the CocH3-Fc forms
examined. The A1V/D142E/L144M mutations on the Fc region prolonged the
biological half-life of the CocH3-Fc by ~21 hours. The other two CocH3-Fc forms, i.e.
CocH3-Fc(M1) and CocH3-Fc(M2), as the Fc region actually shortened the biological
half-life of CocH3-Fc compared to Fc(WT), although Fc(M1) and Fc(M2) successfully
prolonged the biological half-lives of other fusion proteins
Fc(WT).
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(204, 205)

compared to

Figure 5.2 Time-dependent normalized CocH activity of various CocH3-Fc forms. For
convenience, CocH3(FL) represents the full-length (FL) CocH3, whereas CocH3
(without indicating “FL”) refers to the truncated CocH3 (amino-acid residues 1-529).
Rats (n=3 for each dose condition) were injected (IV) with the enzyme
(CocH3(FL)-Fc(M3) or CocH3-Fc(M3)) at a dose of 0.06 mg/kg body weight. Blood
samples were collected at various time points, and the separated plasma samples were
analyzed by using a sensitive radiometric assay using [3H](-)-cocaine. This figure came
from ref.(48).
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Figure 5.3 Molecular structure of CocH3(FL)-Fc. Compared to the CocH3-Fc structure
depicted in Figure 5.1D, the only difference is that CocH3(FL)-Fc shown in this figure
has extra 45 amino-acid residues (forming an -helix) existing between the CocH3 and
Fc regions. Here, CocH3 refers to the truncated CocH3 consisting of the first 529
amino-acid residues the enzyme, whereas CocH3(FL) represents the full-length
enzyme consisting of 574 amino-acid residues. This figure came from ref.(48).
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Figure 5.4 Time-dependent normalized CocH activity of various CocH3-Fc forms. Rats
(n=3 for each dose condition) were injected (IV) with the enzyme at a dose of 0.06
mg/kg body weight. Blood samples were collected at various time points, and the
separated plasma samples were analyzed by using a sensitive radiometric assay using
[3H](-)-cocaine. This figure came from ref.(48).
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5.4 Dose dependence of the enzyme activity in comparison with TV-1380
To further characterize the most promising CocH3-Fc form, CocH3-Fc(M3), we
developed a stable cell line using a lentiviral vector

(83)

to produce CocH3-Fc(M3) in

large-scale. The purified CocH3-Fc(M3) is indeed a dimer as expected (see Figure 5.5).
The in vitro kinetic parameters of the fused CocHs are essentially the same as the
corresponding unfused CocHs (see Figure 5.1B and D and Figure 5.6 for the
determined kcat and KM values).
As seen in Figure 5.7, the biological half-life of CocH3-Fc(M3) (injected IV) in rats
is independent of the dose and, therefore, the CocH3-Fc(M3) concentration at a given
time point is linearly proportional to the dose. Depicted in Figure 5.9 are the
time-dependent maximum CocH activity against cocaine: Vmax  kcat[E] where [E]
represents the concentration of the enzyme (CocH3-Fc(M3) or Albu-CocH1) in rat
plasma. Vmax = 1 U/L means that the enzyme is capable of hydrolyzing up to 1 µmole
cocaine in 1 liter of plasma per minute (i.e. 1 µM min-1). The data in Figure 5.8 indicate
that CocH3-Fc(M3) is far superior to Albu-CocH1 (TV-1380). In particular, after
injection of 5 mg/kg Albu-CocH1 (TV-1380), the rat plasma had Vmax ≥ 50 U/L within
~48 hours. In comparison, Vmax ≥ 50 U/L within ~100 hours after 0.2 mg/kg
CocH3-Fc(M3) injection and ~275 hours after 0.6 mg/kg CocH3-Fc(M3) injection.
Even a tiny dose (0.06 mg/kg) of CocH3-Fc(M3) produced a larger Vmax value in the
plasma compared to that produced by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~80
hours after the CocH (CocH3-Fc(M3) or Albu-CocH1) injection; 0.2 mg/kg
CocH3-Fc(M3) generated a larger Vmax value in the plasma compared to that generated
by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~38 hours after the CocH injection; and
0.6 mg/kg CocH3-Fc(M3) led to a larger Vmax value in the plasma compared to that
generated by 5 mg/kg Albu-CocH1 (TV-1380) starting at ~18 hours after the CocH
injection.
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Figure 5.5 Coomassie-Blue stained SDS electrophoresis gel of the purified
CocH3-Fc(M3) (Marker – protein ladder; Native – native state; Reduced: under
reducing conditions), supporting that the native structure of the purified CocH3-Fc(M3)
was a dimer. This figure came from ref.(48).
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Figure 5.6 Kinetic data obtained in vitro for (-)-cocaine hydrolysis catalyzed by
CocH3-Fc(M3) and Albu-CocH1 (TV-1380). All measurements were in triplicate
(n=3). The reaction rate is represented in M min-1 per nM enzyme. Based on the
Michaelis-Menten analysis, kcat = 5,700 min-1 and KM = 2.8 µM for CocH3-Fc(M3)
against (-)-cocaine, and kcat = 3,080 min-1 and KM = 3.0 µM for Albu-CocH1 against
(-)-cocaine. This figure came from ref.(48).
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Figure 5.7 Time-dependent normalized CocH activity of CocH3-Fc(M3). Rats (n=3 for
each dose condition) were injected (IV) with the enzyme at a dose of 0.06, 0.2, and 0.6
mg/kg body weight. Blood samples were collected at various time points, and the
separated plasma samples were analyzed by using a sensitive radiometric assay using
[3H](-)-cocaine. This figure came from ref.(48).
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Figure 5.8 Time-dependent normalized CocH activity or Vmax (U/L) of CocH3-Fc(M3)
and Albu-CocH1 (or TV-1380). Rats (n=3 for each dose condition) were injected (IV)
with the enzyme (CocH3-Fc(M3) or Albu-CocH1) at a dose of 0.06 mg/kg body weight
unless indicated explicitly otherwise. Blood samples were collected at various time
points, and the separated plasma samples were analyzed by using a sensitive
radiometric assay using [3H](-)-cocaine. This figure came from ref.(48).
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5.5 Cocaine clearance accelerated by CocH3-Fc(M3)
In a further in vivo test, rats were injected with a single dose of CocH3-Fc(M3) (0.2
mg/kg, IV on Day 0), followed by IV injection of cocaine (5 mg/kg) on Days 8, 11, 14,
and 20. After each cocaine injection, blood samples were collected at 2, 5, 10, 15, 30,
and 60 min and analyzed for the concentrations of cocaine and benzoic acid (cocaine
metabolite). The control curves in Figure 5.9 reflect the overall effects of all possible
cocaine elimination pathways (83, 124, 206). In the control rats, the average concentration
of cocaine at the first time point (2 min) was ~7.4 μM, while the average concentration
of benzoic acid was ~0.2 μM. In the presence of CocH3-Fc(M3) on Day 8 after
CocH3-Fc(M3) injection, the average concentration of cocaine at ~2 min in the blood
sample was below 1 μM (~0.9 μM, see Figure 5.9A), while the average concentration
of benzoic acid at the first time point (2 min) was ~11 μM (Figure 5.9B). So,
CocH3-Fc(M3) hydrolyzed nearly all of the cocaine molecules within ~2 min after the
cocaine injection on Day 8. According to the data in Figure 5.9B, the overall enzyme
activity in rats gradually decreased from Day 8 to Days 11, 14, and 20 as expected. But
the CocH3-Fc(M3) activity in rats at even such a low dose (0.2 mg/kg) was still
significant after 20 days.
It should be pointed out that CocH3-Fc(M3) is constructed from human protein
sequences with mutations on only a few residues. As the human protein sequences
associated with CocH3-Fc(M3) are different from the corresponding rodent protein
sequences, we did not try to examine the potential antigenicity/immunogenicity of
CocH3-Fc(M3) in animals in this study. However, according to clinical data reported
for TV-1380 (91), one can reasonably assume that CocH3-Fc(M3) would induce none, a
weak, or merely a transient immune response in humans. The fact that the
CocH3-Fc(M3) was effective in these animals for 20 days suggests that this assumption
might be true.
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5.6 Effectiveness of CocH3-Fc(M3) in blocking the physiological effects of cocaine
In animal behavior studies, mice were injected (IV) with a single dose (2 or 0.2 or 0
mg/kg) of CocH3-Fc(M3) on Day 0, followed by multiple sessions of intraperitoneal
(IP) injection of cocaine (15 mg/kg) and hyperactivity (measured by increased
horizontal distance traveled) recording after 1 hour and 24 hours (Day 1) and then every
other day (Days 3, 5, 7, 9, 11, 13, and 15). For each session, the hyperactivity recording
started 30 min prior to cocaine injection. Data recorded for these sessions are depicted
in Figure 5.10A to H. The data show that CocH3-Fc(M3) completely blocked
cocaine-induced hyperactivity one day (24 hours) after the 0.2 mg/kg CocH3-Fc(M3)
injection, and still significantly attenuated cocaine-induced hyperactivity even after 11
days. At a dose of 2 mg/kg, CocH3-Fc(M3) completely blocked cocaine-induced
hyperactivity within 9 days, and still significantly attenuated cocaine-induced
hyperactivity even after 15 days.
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Figure 5.9 Cocaine clearance accelerated by CocH3-Fc(M3). Saline or 0.2 mg/kg
CocH3-Fc(M3) was injected IV in rats (n=4), followed by IV injection of 5 mg/kg
cocaine after 8, 11, 14, and 20 days. After each IV injection of 5 mg/kg cocaine, blood
samples were collected at 2, 5, 10, 15, 30, and 60 min, and analyzed for the
concentrations of (A) cocaine and (B) benzoic acid (a metabolite of cocaine). This
figure came from ref.(48).
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Figure 5.10 Effects of CocH3-Fc(M3) on cocaine-induced hyperactivity in mice.
Hyperactivity test (n=8 for each dose condition): Saline or CocH3-Fc(M3) (enzyme)
was injected IV, followed by multiple sessions of locomotor activity tests with IP
injection of 15 mg/kg cocaine or saline after 1 hour and 24 hours (one day) and then
every other day. Panels (A) to (H) respectively refer to the locomotor activity sessions
on Days 1, 3, 5, 7, 9, 11, 13, and 15 after the CocH3-Fc(M3) injection. For each
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locomotor activity session, the locomotor activity recording started at 30 min prior to
the cocaine injection. This figure came from ref.(48).
5.7 Effectiveness of CocH3-Fc(M3) in blocking the lethal effects of cocaine
It is well-known that cocaine is lethal when the dose is high, with LD50 (the lethal
dose which causes the death of 50% of a group of test animals) = 14 mg/kg (IV) (207) or
95.1 mg/kg (IP) (208) for mouse. To examine how long CocH3-Fc(M3) can protect mice
from the acute toxicity of a lethal dose of cocaine, mice were injected with a single dose
of CocH3-Fc(M3) (2 mg/kg, IV) on Day 0, followed by a lethal dose of cocaine (100
mg/kg, IP) every day (starting on Day 4) until convulsion occurred (end point of the
toxicity test) for a given mouse. For the control group (without CocH3-Fc(M3)
injection), all mice had convulsions within minutes after the first cocaine challenge,
and 60% of the mice died soon after convulsion. For the test group receiving 2 mg/kg
CocH3-Fc(M3), convulsions occurred only during the final cocaine challenge after
10.2 days in average; convulsions did not occur during the daily cocaine challenge
within 9.2 days in average. The average protection time <tp> provided by 2 mg/kg
CocH3-Fc(M3) is 9.7 ± 1.7 days. Thus, injection of 2 mg/kg CocH3-Fc(M3) can
effectively protect mice from the acute toxicity of the lethal dose of cocaine (100 mg/kg,
IP) for nearly 10 days.
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Figure 5.11 Effects of CocH3-Fc(M3) on cocaine-induced toxicity in mice. Toxicity
test (n=5): A single dose of CocH3-Fc(M3) (2 mg/kg, IV) was followed by a daily
dosing of cocaine (100 mg/kg, IP) starting on Day 4 until convulsions occurred (end
point of the toxicity test) for a given mouse. For a given mouse, if convulsions occurred
during the final cocaine challenge on Day m, but did not occur during the cocaine
challenge on and before Day m-1, then the protection time (tp) for this mouse was
considered as between m-1 and m days: m-1 < tp > m or tp = m-1/2 days. <tp> represents
the average tp value for all mice in the group. This figure came from ref.(48).
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5.8 Perspectives in clinical development of cocaine hydrolase for cocaine addiction
treatment
We have successfully designed a novel long-acting cocaine-metabolizing enzyme
form, CocH3-Fc. The optimized CocH3-Fc entity, CocH3-Fc(M3), indeed has a long
biological half-life like an antibody, but with an unprecedentedly high catalytic
efficiency compared to all catalytic antibodies known to date. Compared to the most
active anti-cocaine catalytic antibody 15A10 (kcat = 2.3 min-1, KM = 220 µM, and t1/2 <
24 hours in rats)

, the CocH3-Fc(M3) has an even significantly longer biological

(209)

half-life (kcat = 5,700 min-1, KM = 2.8 µM, and t1/2 = ~107 hours in rats) and
~200,000-fold improved catalytic efficiency against cocaine. The long-acting
CocH3-Fc(M3) is highly efficient in blocking the physiological and toxic effects of
cocaine for a long period of time. Further, it is well known that a protein drug generally
has a significantly longer biological half-life in humans compared to that in rats, e.g. t1/2
= 3-6 days in rats and 12-23 days in humans for abatacept, Fc(M1)-fused human
cytotoxic lymphocyte associated antigen (204). Thus, one may reasonably expect that an
appropriately chosen dose of CocH3-Fc(M3) may effectively prevent both relapse and
overdose for 2-4 weeks or longer during cocaine addiction treatment for humans.
The general strategy of developing a long-acting drug-metabolizing enzyme for the
treatment of cocaine abuse may also be useful in the development of long-acting forms
of other therapeutic enzymes. To develop a truly long-acting enzyme form fused with
Fc, one must structurally optimize both the enzyme and Fc portions of the Fc-fused
enzyme. Further, even if the protein fusion with Fc can really prolong the biological
half-life of a therapeutic protein, the data obtained in this investigation demonstrate that
certain amino-acid mutations on the Fc portion that can prolong biological half-life of
an Fc-fused therapeutic protein may not necessarily prolong the biological half-life of
another Fc-fused therapeutic protein.
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Chapter 6: Concluding Remarks and Future Plan

Enzyme therapy using an efficient cocaine-metabolizing enzyme is recognized as
the most promising treatment strategy for cocaine overdose and addiction

.

(16, 86, 91, 92)

While the thermal instability and low catalytic activity against cocaine limit the clinical
use of wild-type bacterial CocE and human BChE, site-directed mutagenesis based on
molecular modeling have solved these problems and created efficient and thermally
stable cocaine-metabolizing enzymes, that are mutants of CocE and BChE, as
promising anti-cocaine medications
(T172R/G173Q)

, known as RBP-8000

(88)

. A thermally stable CocE mutant

(88, 89, 102-104, 148)

, is currently in clinical development for

(90)

cocaine overdose treatment; the human clinical trial Phase IIa has been completed,
showing that the CocE mutant is safe and effective in hydrolyzing cocaine

, but

(90)

inactive against BE (a major, biologically active metabolite of cocaine)

.

(4)

Theoretically speaking, CocHs should be more promising candidates for the treatment
of not only cocaine overdose, but also cocaine addiction, due to a relatively higher
catalytic activity against cocaine, and longer biological half-life. However, whether
CocHs can degrade BE into biological inactive metabolites remain to be one of the
main concerns for cocaine overdose treatment as no metabolic enzyme of BE has ever
been reported in literature. In addition, while TV1380, an HSA-fused CocH, showed
some promise for cocaine addiction treatment, its actual therapeutic value for cocaine
addiction treatment is still limited by the moderate biological half-life which is ~8 hr
in rats (86) or 43-77 hr in humans (91). Thus, to address these two problems and some
other concerns in further development of CocHs for the treatment of cocaine overdose
and addiction, in the investigation described in this thesis, we have carried out kinetic
characterization of an hCocH and a mCocH for their catalytic activities against cocaine
and other substrates, identified enzymes that can hydrolyze not only cocaine, but also
its long-lasting metabolite benzoylecgonine, developed a LC-MS/MS method for
determining pharmacokinetic profiles of cocaine and metabolites, and developed a
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long-acting form of hCocH.
6.1 Summary of the major conclusions obtained from this investigation
1) Enzymes mCocH and hCocH have improved the catalytic efficiency of mBChE
and hBChE against (-)-cocaine by ~8- and ~2000-fold, respectively, although the
catalytic efficiencies of mCocH and hCocH against other substrates, including ACh and
BTC, are close to those of the corresponding wild-type enzymes mBChE and hBChE.
According to the kinetic data, the catalytic efficiency of mBChE against (-)-cocaine is
comparable to that of hBChE, but the catalytic efficiency of mCocH against (-)-cocaine
is remarkably lower than that of hCocH by ~250-fold. The remarkable difference in the
catalytic activity between mCocH and hCocH is consistent with the difference between
the enzyme-(-)-cocaine binding modes obtained from molecular modeling.
2) We have demonstrated for the first time that plasma enzyme BChE is the
endogenous metabolic enzyme of BE and the BChE mutant E12-7 with significantly
improved catalytic efficiency against BE compared to wild-type BChE may be used as
an exogenous enzyme to effectively accelerate BE hydrolysis in the body for cocaine
overdose treatment. Compared to RBP-8000 (the T172R/G173Q mutant of CocE) (88, 90)
under current clinical development for cocaine overdose treatment, E12-7 is not only
more efficient against cocaine (102), but also effective in hydrolyzing BE. Hence, E12-7
should be a more promising therapeutic candidate for cocaine overdose treatment in
comparison with the T172R/G173Q mutant of CocE, although one would like to
further improve the catalytic efficiency against BE for cocaine overdose treatment.
3) We have successfully developed a simple and rapid LC-MS/MS method
combined with one-step solid phase extraction to simultaneously determine the
concentrations of cocaine, EME, BE, ECG, norcocaine, NEME, cocaethylene, EEE,
norcocaethylene, and NEEE in the rat blood samples. Great specificity, sensitivity,
linearity, recovery, accuracy, precision, and stability of the method have been well
demonstrated. With a successful application to a pharmacokinetic study in rats with
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co-administration of cocaine and alcohol, this method will be valuable for further
studies that aim to characterize anti-cocaine therapeutic agents and their effects on
metabolic profiles of cocaine in the presence/absence of alcohol.
4) We have developed a novel CocH form, catalytic antibody analog, which is an
Fc-fused CocH dimer (CocH-Fc) constructed by using CocH to replace the Fab region
of human immunoglobulin G1. The CocH-Fc has not only a high catalytic efficiency
against cocaine, but also a considerably longer biological half-life (e.g. ~107 hours in
rats) like an antibody. A single dose of CocH-Fc was able to accelerate cocaine
metabolism in rats even after 20 days and, thus, block cocaine-induced hyperactivity
and toxicity for a long period of time. In consideration of the general observation that
the biological half-life of a protein drug in humans is significantly longer than that in
rodents, the CocH-Fc reported in this study could allow dosing once every 2-4 weeks,
or longer for cocaine addiction treatment in humans. The long-acting enzyme approach
may provide a novel, truly promising therapy capable of effectively blocking the
physiological and toxic effects of cocaine without affecting normal functions of the
brain and other critical organs and prevent relapse during abstinence.
6.2 Future plan concerning rational design of CocHs for cocaine abuse
1) To further improve the catalytic efficiency of CocH against BE for cocaine
overdose treatment;
2) To further characterize the detailed toxicological and pharmacological profiles
of CocH-Fc, such as the effectiveness, selectivity, and duration of CocH-Fc’s actions in
cocaine self-administration and discrimination;
3) To optimize a promising CocH form which has not only a higher catalytic
activity against cocaine, but also a longer in vivo half-life compared to CocH-Fc;
4) The most promising CocH form optimized in the further investigation will
possiblely be ready for cGMP (current Good Manufacturing Practices) protein
manufacturing and subsequent clinical trials.
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